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Advanced urothelial cancer (UC) is an aggressive disease with high morbidity and mortality. 
The primary aim of this thesis was to improve chemotherapy with respect to treatment efficacy, 
safety, and health-related quality of life (HRQoL) in advanced UC. The recently introduced 
chemotherapeutical drug vinflunine was investigated as monotherapy and in novel treatment 
combinations for metastatic UC (mUC). Further, two different neoadjuvant chemotherapy 
regimens were evaluated in muscle-invasive bladder cancer (MIBC). 
Platinum-based combination chemotherapy have been standard treatment in mUC patients 
since the late 1980s. Vinflunine, approved in 2009, show a small but important improvement 
in survival when given as second line treatment. In Paper I, patients treated with vinflunine 
were evaluated in a retrospective real-world data study. The results confirmed that vinflunine 
is an active drug in an unselected cohort of routine patients. Further, patients with poor 
performance status had short survival and a high frequency of adverse events. 
With the aim of further improving the efficacy of second-line treatment of  mUC, vinflunine 
was combined with sorafenib in the dose-finding phase I trial VINSOR (Paper II). A 
recommended phase II dose could be identified. The adverse events generally agreed with those 
previously reported for vinflunine and sorafenib as monotherapy. The novel combination 
generated clinically meaningful disease stabilisation and tumour responses. 
There is an unmet medical need for new treatment options for cisplatin-ineligible patients in 
first-line mUC, which was addressed in the randomised phase II trial VINGEM (Paper III)       
that compared the experimental combination of vinflunine and gemcitabine (VG) and standard 
treatment with gemcitabine and carboplatin. Compared to standard treatment, VG did not 
improve the primary endpoint progression-free survival. However, patients treated with VG 
did show a notably high overall response rate that was similar to the best data reported for any 
systemic therapy for mUC. The toxicity profile for VG was generally manageable, although 
high rates of neutropenia and febrile neutropenia were observed. No significant differences in 
HRQoL were found between the two treatment arms. 
For patients with MIBC, neoadjuvant cisplatin-combination chemotherapy prior to cystectomy 
improves overall survival, but the optimal regimen is still unknown. A more cisplatin-dose-
intense 3-week schedule was compared with a 4-week schedule of gemcitabine and cisplatin 
(GC) as neoadjuvant treatment in a retrospective study (Paper IV). Compared to the 4-week 
schedule, the 3-week schedule led to a significantly higher degree of pathological complete 
response, although this was associated with more frequent neutropenia. Despite the differences 
in downstaging, no differences in survival were observed between the two schedules. 
In summary, vinflunine is an active drug for second-line treatment of mUC patients in a real-
world setting. The novel combination of vinflunine and sorafenib can be safely combined in 
second-line treatment. In cisplatin-ineligible patients, compared to standard first-line treatment, 
the experimental combination of VG shows a higher response rate but does not prolong 
survival. In patients with MIBC, a more cisplatin-dose-intense 3-week schedule achieves 
significantly more complete responses compared to a 4-week schedule of GC as neoadjuvant 
chemotherapy prior to cystectomy. 
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1.1 INTRODUCTION TO ADVANCED UROTHELIAL CANCER 
Urothelial cancer (UC) is a major global health concern and ranges from superficial non-
muscle-invasive tumours with good prognosis to muscle-invasive tumours of the bladder and 
deadly metastatic disease. This dissertation is focused on advanced UC, defined as muscle-
invasive bladder cancer (MIBC) and metastatic urothelial cancer (mUC), the latter of which 
also includes locally unresectable tumours. Advanced UC is a highly aggressive disease 
associated with substantial morbidity and mortality [1, 2]. There is a need to improve medical 
treatment, including chemotherapy, for patients with MIBC and mUC in order to increase 
survival, decrease treatment-related side effects, and improve quality of life. An overview of 
the current treatment options in MIBC and mUC is presented in Figure 1. 
The standard treatment for patients with MIBC consists of cisplatin-based neoadjuvant 
chemotherapy followed by radical cystectomy. Despite intense treatment, the median 5-year 
survival is only about 50% [1, 2], mainly due to treatment failure and development of distant 
metastases. 
Metastatic UC is a lethal disease with an overall survival (OS) of only roughly 6 months 
without treatment and approximately 15 months with the best treatment options available today 
[1, 2]. For patients with mUC, platinum-based combination chemotherapy has been the 
standard treatment since the late 1980s, displaying a high overall response rate (ORR) [3]. 
However, the duration of the responses is generally short, and adverse events are a common 
clinical challenge. Vinflunine was approved as second-line treatment in 2009, and has led to a 
small but important improvement in the survival of patients with mUC [4]. The development 
of immunotherapy has been a major breakthrough in many cancer diagnoses, as well for          
treatment of UC [5]. However, the response rate to immunotherapy in mUC is rather low, 
emphasising the importance of chemotherapy as a cornerstone in the treatment of this severely 
ill patient population. 
 
 
Figure 1. Schematic overview of the present treatment options for patients with MIBC and mUC.  
MVAC,  methotrexate, vinblastine, doxorubicin and cisplatin; PCG, paclitaxel, cisplatin and gemcitabine. 
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The following sections present a literature review focused on chemotherapy treatment of MIBC 
and mUC patients with the aim of providing the background and rationale for performing the 
four studies included in this thesis.  
 
1.1.1 Epidemiology and etiology 
UC consists of primary cancers from the urinary collection systems originating in the urinary 
bladder (approximately 95% of the cases), renal pelvis, ureter and urethra [1]. The majority of 
UCs arise from the urothelium (transitional epithelial cells) lining the mucous membranes of 
the urinary tract. About two thirds of UC cases are non-muscle invasive, and approximately 
one third are muscle invasive and locally unresectable or primary metastatic at diagnosis. 
UC is a common cancer associated with high mortality. The global incidence is about 550 000 
cases annually [6], and UC is the twelfth most common cancer worldwide. In Sweden, UC is 
the seventh most frequent cancer, with 3402 new cases in 2018 [7]. Mortality in UC is high at 
an annual rate of 200 000 deaths globally and around 750 deaths in Sweden. According to the 
Swedish National Registry of Urinary Bladder Cancer (SNRUBC), approximately 23% of the 
cases in Sweden are muscle invasive at diagnosis [8]. 
The aetiology of UC is multifactorial and not fully known. Age and sex are important risk 
factors [7, 9], with a mean age of 70 years at diagnosis and a male-to-female ratio of 2–3:1. 
The most common external risk factor for UC is tobacco, and it is estimated that approximately 
50% of the cases are associated with cigarette smoking [10]. Exposure to certain chemicals, 
mainly aromatic amines, is also an important risk factor for UC [11]. Radiotherapy to the pelvis 
region and specific chemotherapy (e.g., cyclophosphamide, melphalan, and thiotepa) may 
cause secondary malignancy in the urothelial tract [12-14]. Infection with the parasite 
Schistosoma is distinctly associated with an increased risk of squamous cell carcinoma of the 
bladder [15], and such infection is common in developing countries, particularly in Africa and 
the Middle East.  
 
1.1.2 Clinical presentation and classification 
Haematuria is the most typical alarm symptom for UC and should be investigated rapidly. 
Approximately one out of three patients with macroscopic haematuria are diagnosed with a 
tumour in the urinary tract or in the prostate, and about 75% of patients with UC experience 
haematuria at the time of diagnosis [16]. For patients with locally advanced disease, growth of 
the tumour in the pelvis can cause severe symptoms such as pain, haematuria, hydronephrosis, 
and renal failure [1, 2]. Regional lymph node metastases in the abdomen and pelvis are 
common. Distant metastases are most often located in the lungs, liver, bone, and central 
nervous system. 
UC is diagnosed through cystoscopy, transurethral resection of the bladder (TUR-B), 
histopathological assessment of the tumour lesion, and radiological imaging [1, 2]. Bladder 
cancer is staged according to the TNM classification [17] and is divided into two main groups: 
non-muscle-invasive tumours (Ta, CIS, and T1) and muscle-invasive tumours (T2–T4N0M0). 
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Computerised tomography (CT) and magnetic resonance imaging (MRI) are the diagnostic 
radiological methods most frequently used to stage the primary tumour, the regional lymph 
nodes, and distant metastases (together designated TNM) [1, 2]. However, correlation is low 
between the preoperative clinical (i.e., radiological) T stage and the pathological stage after 
cystectomy. Some studies have shown accuracy to be as low as 50%, where CT tends to 
underestimate [18] and MRI overestimate [19] the T stage. Histopathological assessment 
provides the tumour grade according to the World Health Organization (WHO) classification 
of tumours of the urinary system 2016 [20]. 
 
1.1.3 Molecular biology 
In recent years, extensive research has increased the knowledge regarding the molecular 
biology of UC [21-23]. It is postulated that UC develops along two distinct molecular 
pathways: papillary non-muscle-invasive UC that has a good prognosis, and non-papillary 
genetically unstable MIBC that arises from carcinoma in situ and has a poor prognosis  [24].         
Nevertheless, UC shows wide heterogeneity in molecular features that are independent from 
conventional staging such as TNM stage and WHO grade [23]. 
Molecular classification of UC has been established suggesting three major molecular 
subtypes, luminal, basal and neuroendocrine differentiation, with several possible subgroups 
[25]. The subtypes are characterized by different alterations in important tumor biology 
hallmarks, e.g. cell-cycle regulation, immune signaling, tyrosine receptor kinases pathways, 
cytokeratin alterations, cell adhesion mechanisms and mutations in FGFR3, PI3KCA and p53. 
Furthermore,  molecular subtypes show distinct clinical outcomes, e.g. patients with the 
subgroup “luminal papillary” show good prognosis and patients with basal differentiation poor 
prognosis [25, 26].  
 
1.2 SYSTEMIC TREATMENT IN MUSCLE INVASIVE BLADDER CANCER 
(MIBC) 
Radical cystectomy is the standard curative treatment for patients with MIBC, but the relapse 
rate is high. The 5-year recurrence-free survival is reported to be 30–52% [2, 27], with local 
recurrences arising in 5–15% of the patients and metastatic disease in 20–50% [2, 27, 28]. 
External beam radiotherapy with concomitant chemotherapy is an alternative curative-intent 
treatment for MIBC, and it offers local control and survival rates comparable to radical 
cystectomy [29]. About 50% of the patients with MIBC are considered ineligible for curative 
therapies due to high age, poor performance status (PS), or comorbidities [8, 30]. Thus, there 
is a great need for improved treatment strategies for patients with MIBC. 
 
1.2.1   Neoadjuvant treatment 
In MIBC, neoadjuvant cisplatin-based chemotherapy improves OS compared to radical 
cystectomy alone. The purpose of preoperative chemotherapy is to reduce the primary tumour 
in the bladder and to eradicate micrometastases. In the 1980s and 1990s, neoadjuvant cisplatin-
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based chemotherapy was investigated in several randomised trials. Three large meta-analyses 
concluded that neoadjuvant treatment reduced the risk of death by 10–14% and led to a 5% 
increase in absolute median overall survival (mOS) at 5 years in comparison with cystectomy 
alone [31-33]. The cited trials were heterogeneous in terms of patient characteristics, type of 
cisplatin combinations, and primary therapy (cystectomy and/or radiotherapy). The different 
cisplatin-based regimens have not been investigated head-to-head in randomised clinical trials. 
For patients ineligible for cisplatin due to impaired renal function, poor PS, or comorbidities, 
there is no evidence-based treatment available for use in the neoadjuvant setting [34]. The 
combination methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) has been studied 
in a randomised phase III trial that showed a significant 5-year mOS advantage compared to 
cystectomy alone (57% vs 43%) [35], and MVAC is commonly used as a neoadjuvant regimen. 
The combination of gemcitabine and cisplatin (GC) is also frequently used in the neoadjuvant 
setting based on the results of a randomised phase III mUC trial in which GC and MVAC had 
similar response rates and survival outcomes, but GC had a more favourable toxicity profile 
[36]. No neoadjuvant randomised phase III trials with GC have yet been performed. 
A large number of retrospective real-world data (RWD) studies have been performed to address 
the efficacy of MVAC and GC as neoadjuvant treatment in patients with MIBC. The largest 
investigation thus far included 785 patients, and it indicated that MVAC and GC had similar 
pathological complete response rates (pT0N0) of approximately 25%, and similar partial 
downstaging (< pT2N0) of approximately 45%, along with no significant difference in survival 
[37]. Pooled data in meta-analyses summarise pathological response rates (pT0N0 and 
< pT2N0) and survival in the same range for GC as for MVAC [38-41]. Dose-dense (dd) 
regimens in combination with granulocyte colony-stimulating factor (G-CSF) have been 
explored, and show promising downstaging rates and tolerable toxicity profiles (dd-MVAC 
[42-45] and dd-GC [46, 47]). To a large extent, dd-MVAC has replaced conventional MVAC 
as neoadjuvant treatment in clinical practice [1]. Different doses and numbers of cycles of 
MVAC, dd-MVAC, and GC have been used, but the optimal neoadjuvant regimen is not yet 
known. For GC, the most commonly used neoadjuvant schedule is either four cycles of a more 
cisplatin-dose-intense 3-week schedule or three cycles of a commonly applied 4-week 
schedule. In mUC, these two GC schedules appear to be similarly efficient, although with less 
haematological toxicity in the 3-week schedule [48]. In the neoadjuvant setting, the preferable 
GC schedule has not been determined. The aim of the study reported in Paper IV was to 
compare the 3-week and the 4-week schedule of GC as neoadjuvant treatment in patients with 
MIBC with respect to treatment patterns, toxicity, downstaging efficacy, and survival. 
Pathological complete response (pT0N0) at cystectomy after neoadjuvant chemotherapy in 
patients with MIBC is suggested to be a surrogate marker for the overall treatment efficacy. 
Patients with pT0N0 have a significantly better prognosis than patients without complete 
downstaging, showing 5-year survival rates of approximately 85–90% and 50%, respectively 
[35, 49, 50]. Rosenblatt et al. [49] demonstrated increased survival of approximately 30% in 
patients who achieved complete response due to neoadjuvant chemotherapy compared to those 
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who achieved pT0 after TUR-B only, which illustrates the importance of treating possible 
micrometastases. 
Besides chemotherapy, immunotherapy with immune checkpoint inhibitors (ICIs) are 
presently being explored in the neoadjuvant setting. Monotherapy with pembrolizumab and 
with atezolizumab provided promising results in single phase II trials with pT0N0 of 42% and 
31%, respectively, in patients with MIBC [51, 52]. Several randomised neoadjuvant phase II 
and III trials including ICIs as monotherapy or in combination with chemotherapy are ongoing, 
but as of yet no data are available from these studies [5, 34]. 
 
1.2.2 Adjuvant treatment 
Adjuvant chemotherapy after radical cystectomy in patients with MIBC has been evaluated in 
several trials, although the findings are inconsistent with regard to potential survival 
advantages. Two meta-analyses indicated a 25% reduction in mortality and a 9% increase in 
OS at 3 years, but the trials included in those meta-analyses were criticised for small sample 
sizes, flaws in trial design, and statistical considerations [53, 54]. A phase III trial comparing 
immediate versus delayed (at time of visible relapse) chemotherapy for patients with residual 
tumour at cystectomy (pT3–pT4 or node-positive disease) did not show any survival advantage 
for immediate compared to delayed treatment, although an increase in 5-year median 
progression-free survival (mPFS) was observed [55]; unfortunately, this trial had low statistical 
power. In conclusion, adjuvant chemotherapy is not generally recommended as standard 
treatment after cystectomy due to lack of evidence, but it can be considered in selected patients 
with advanced or node-positive disease who have not received neoadjuvant chemotherapy [1, 
2]. 




Figure 2. Timeline of the positive landmark mUC trials.  
MVAC, methotrexate, vinblastine, doxorubicin and cisplatin; PCG, paclitaxel, cisplatin and gemcitabine. 
 
1.3.1 First-line treatment  
The standard treatment for non-curable locally unresectable (cT4b and/or N1-3) or 
metastasised UC has been platinum-based combination-chemotherapy since the late 1980s. In 
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1989, a trial with MVAC showed an impressive ORR of 72% and mOS of 14.8 months [3]. 
However, MVAC is associated with considerable toxicity: 3% drug-related deaths, 25% 
neutropenic fever, 58% myelosuppression, and 49% mucositis. With high-dose MVAC (HD-
MVAC), a dose of cisplatin that is twice as high as in classic MVAC is given together with G-
CSF [56, 57]. Compared to MVAC, HD-MVAC induces a significantly higher ORR (64% vs 
50%) but no significant increase in mOS (15.1 vs 14.9 months). Also, due to the addition of G-
CSF, HD-MVAC causes less neutropenia and neutropenic fever compared to MVAC. 
A randomised phase III trial, presented in 2000, compared GC with MVAC and demonstrated 
no significant difference in either ORR (46% vs 49%) or mOS (13.8 vs 14.8 months) but did 
show a better safety profile for GC [36, 58]. The patients in the GC arm in comparison with 
the subjects given MVAC displayed significantly less grade 3/4 neutropenia (71% vs 82%), 
neutropenic fever (3% vs 26%), and grade 3/4 mucositis (1% vs 22%). Therefore, due to the 
more favourable safety profile, GC has to a large extent replaced MVAC as the standard first-
line treatment in mUC [1, 2]. 
The taxanes paclitaxel and docetaxel have been investigated in single, doublet, and triplet 
regimens for mUC [59]. Doublet regimens combining a taxane and a platinum agent 
(docetaxel/cisplatin [60] and paclitaxel/carboplatin [61]) have induced similar or inferior 
responses and survival compared to MVAC. Various triplet regimens have been investigated 
in single-arm phase II trials with promisingly high response rates and OS [59]. However, only 
one randomised phase III trial including three chemotherapeutical drugs for mUC has been 
completed, and it compared GC alone with GC plus paclitaxel (PCG) [62]. Adding paclitaxel 
to GC did not significantly improve the mOS compared to GC alone (15.8 months vs. 12.7 
months), although it did result in a significant increase in ORR (56% vs 44%). It should also 
be noted that a higher degree of neutropenic fever was seen in the triplet arm PCG. 
 
1.3.2 First-line treatment in cisplatin-ineligible patients 
Approximately half of all patients with mUC are ineligible (“unfit”) for cisplatin-based 
chemotherapy due to impaired renal function, poor PS, co-morbidities (e.g., hearing loss, 
peripheral neuropathy, or heart failure), or high age[63]. Being unfit in this context is 
commonly defined as having an Eastern Cooperative Oncology Group performance status 
(ECOG PS) of ≥ 2 and/or a glomerular filtration rate (GFR) of < 60 ml/min [64]. Several 
regimens for treatment of the unfit population have been investigated in multiple small single-
arm phase II trials, including monotherapy and combinations of gemcitabine, carboplatin, 
paclitaxel, oxaliplatin, vinblastine, and epirubicin [63]. 
Only one randomised phase III trial has been reported for patients ineligible for cisplatin and 
that trial compared gemcitabine and carboplatin (GCa) and methotrexate, carboplatin, and 
vinblastine (M-CAVI) [65, 66]. This study showed no significant differences between the two 
treatment arms in ORR (41% vs 30%) or in mOS (9.3 vs 8.1 months), although GCa showed a 
significant favourable toxicity profile (grade 3/4 mucositis, neutropenic fever, renal toxicity, 
and grade 4 thrombocytopenia associated with bleeding and death), 9% for GCa vs 21% for 
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M-CAVI. Patients with both PS ≥ 2 and impaired renal function had shorter mOS, lower ORR, 
and a higher degree of severe acute toxicity. Based on the results of this trial, in most countries 
GCa is considered as the standard first-line treatment for mUC patients unfit for cisplatin [1, 
2]. 
In 2017, immunotherapy with ICIs was approved for first-line treatment of cisplatin-unfit 
patients. In single-arm phase II trials, pembrolizumab [67, 68] and atezolizumab [69], 
respectively, resulted in ORRs of 24% and 23%, and mOS of 11.3 and 15.9 months. The 
toxicity profile for immunotherapy was generally favourable compared to carboplatin-based 
chemotherapy. The most widely reported adverse events (AEs) associated with pembrolizumab 
and atezolizumab were fatigue (18% and 30%), diarrhoea (12%), and pruritus (11% and 18%). 
Decreased renal function occurred in only about 4% of the studied subjects, thus ICIs are 
suitable options for patients that are ineligible for cisplatin treatment due to impaired renal 
function. The efficacy of ICIs varies with the level of expressed programmed death-ligand 1 
receptor (PD-L1), and only approximately 30% of patients with mUC express high levels of 
PD-L1 [70]. Today, the use of pembrolizumab and atezolizumab as first line treatment in mUC 
patients unfit for cisplatin is restricted to individuals with high expression of PD-L1 [71, 72]. 
In 2009 vinflunine was approved as second-line treatment after platinum-based chemotherapy 
for patients with mUC, and since then this drug has been further explored in combination with 
gemcitabine and carboplatin as first-line treatment for cisplatin-ineligible patients. The safety 
of the combinations vinflunine and gemcitabine (VG) and vinflunine and carboplatin (VCa) 
were initially assessed in phase I trials [73, 74]. The randomised phase II trial JASINT1 
compared VG and VCa, and showed promising response rates and survival, although no 
statistical difference was seen between the two groups (ORR 44% for VG and 29% for VCa, 
mOS 14.0 months for VG and 12.8 months for VCa) [75]. A more favourable toxicity profile 
with less grade 3/4 haematological AEs was noted for the VG arm compared to the VCa arm. 
The main criticism of the JASINT1-trial has been that it did not include a non-investigational 
control arm such as GCa. 
Patients with mUC that are ineligible for cisplatin represent a fragile population with inferior 
survival compared to patients that can receive cisplatin combination therapy. Although no 
phase III trial has been conducted to compare cisplatin and carboplatin-based regimens head-
to-head for treatment of mUC, small randomised phase II trials have indicated superiority of 
cisplatin combinations [76-78]. Furthermore, retrospective RWD show a significantly longer 
survival for patients treated with cisplatin-based chemotherapy compared to those given 
carboplatin-based combinations or non-platinum regimens [79, 80]. There is clearly a need to 
develop more effective novel regimens for the cisplatin-ineligible population. To address the 
need for new treatment options for cisplatin-unfit patients in first-line mUC, the randomised 





1.3.3 Second-line treatment and beyond 
Patients with mUC that progress on first-line platinum chemotherapy represent a 
heterogeneous population. Some patients present with good PS and slowly progressing limited 
disease, whereas others display large-volume disease that affects the function of vital organs 
and causes a high degree of comorbidities, poor overall PS, and short survival. The patients in 
this fragile cohort tend to benefit less from chemotherapies due to an increased risk of more 
severe side effects, which also limits the feasibility of and patient accrual in randomised trials.      
Numerous small single-arm phase II trials have investigated different chemotherapy drugs in 
second-line, both as monotherapy and in combinations. Non-platinum drugs such as 
cabazitaxel, docetaxel, ifosfamide, irinotecan, paclitaxel, nab-paclitaxel, and pemetrexed have 
resulted in ORRs of 5–29% [81] and modest mOS data of 5–10 months. Combination treatment 
tends to give higher response rates but has failed to translate this into prolonged survival [82]. 
As already stated, in 2009 vinflunine was the first drug to be approved as second-line treatment 
for patients with mUC. Vinflunine (Javlor®) is a novel microtubule inhibitor with higher levels      
of in vitro and in vivo tumour activity compared to other vinca alkaloids [83]. The efficacy of 
vinflunine was analysed in two phase II trials [84, 85] and further in a randomised phase III 
trial comparing vinflunine plus best supportive care (BSC) to BSC alone [4]. The mOS was 
significantly improved by 2.6 months (6.9 months for vinflunine vs 4.3 months for BSC) in the 
eligible population but not in the intention-to-treat (ITT) population [4, 86]. Vinflunine has 
been approved by the European Medicines Agency (EMA), but it has not been approved by 
the United States Food and Drug Administration (FDA) based on the ambiguity of the statistics 
in the ITT and eligible populations. ORR, disease control rate (DCR), mPFS, and multivariate 
analyses adjusting for prognostic factors all showed statistical significance in favour of 
vinflunine compared to BSC. The most frequent side effects of vinflunine were neutropenia 
(50%), anaemia (19%), febrile neutropenia (6%), fatigue (19%), and constipation (16%) [4]. 
At the time of commence of this dissertation, vinflunine had recently been introduced in routine 
clinical practice, although no RWD studies had been performed that validated the efficacy and 
safety of this drug in an unselected clinical cohort, and this issue is addressed in Paper I. 
One strategy to further improve the outcome for patients progressing on first-line platinum 
treatment is to use vinflunine as a backbone in combination with other drugs. However, phase 
I trials studying vinflunine in combination with the antiangiogenic tyrosine kinas inhibitor 
pazopanib [87] and in combination with the antimetabolite chemotherapeutical drug 
pemetrexed [88] demonstrated that both those combinations were too toxic for further 
evaluation. It has been hypothesised that the antiangiogenic vascular endothelial growth factor 
receptor (VEGFR) multi-tyrosine kinase inhibitor sorafenib (Nexavar®) [89] might be 
effective for treatment of UC due to altered signalling in angiogenic pathways in UC tumours 
[90], and treatment with sorafenib has been investigated in small single-arm trials [91, 92] and 
has also been described in a case report with favourable outcome in one mUC patient [93]. 
Accordingly, the dose-finding phase I trial entitled VINSOR was initiated to assess the safety 
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of the combination of vinflunine and sorafenib, with the long-term aim of improving vinflunine 
treatment in patients with mUC (Paper II).      
Immunotherapy with ICIs is a major breakthrough in mUC. Five ICIs have been approved 
by the FDA for use as second-line treatment in platinum-progressive mUC patients: 
atezolizumab [94], pembrolizumab [95], nivolumab [96], avelumab [97], and durvalumab 
[98]. In Sweden, atezolizumab, pembrolizumab, and nivolumab have been approved. Two 
randomised phase III trials [97, 98] evaluated pembrolizumab and atezolizumab compared 
with the investigators’ choice of chemotherapy (vinflunine, paclitaxel, or docetaxel). The 
trial with pembrolizumab led to significantly prolonged mOS compared to chemotherapy 
(10.3 vs 7.4 months) [95], whereas the atezolizumab trial did not meet the primary endpoint 
of improved survival [94]. The ORR for ICIs in second-line treatment is generally rather low 
at 13–21%, and the mOS is between 8.6 and 18.2 months [99]. However, in patients that do 
respond to ICIs, duration of the response is long. For example, in the phase III trial with 
pembrolizumab, among those patients who did show a response, the response was still 
ongoing at 12 months in 68% in the pembrolizumab group compared to 35% in the 
chemotherapy group [95]. In the two phase III trials, pembrolizumab and atezolizumab 
showed a better safety profile with significantly lower incidence of grade 3/4 AEs compared 
to the control chemotherapy (15% for pembrolizumab and 20% for atezolizumab, and 
approximately 45% for chemotherapy) [94, 95]. For pembrolizumab, the most common side 
effects of all grades were pruritus (20%), fatigue (14%), and diarrhoea (9%), and the most 
frequent immune-related AEs (irAEs) were hypothyroidism (6%), pneumonitis (4%), 
hyperthyroidism (4%), and colitis (2%) [95]. 
For patients that progress on platinum chemotherapy, immunotherapy, and vinflunine, no 
evidence-based treatment options have yet been approved. These patients usually have an 
advanced disease with severe clinical symptoms, poor PS, and short expected survival. If 
eligible for treatment, paclitaxel and gemcitabine can be an option [100, 101], but these 
patients should preferably be included in clinical trials [1, 2]. 
 
1.4 PROGNOSTIC CLINICAL FACTORS AND MOLECULAR MARKERS 
Patients with advanced UC show large inter-individual differences in their responses to the 
available treatments. Prognostic and predictive factors for tumour response and survival are 
essential to individualise the treatment and to improve efficacy outcomes. Such factors can also 
enable stratification of patients in clinical trials [102]. 
Two negative clinical prognostic factors are well established in first-line treatment with 
platinum in mUC, namely the Bajorin factors: performance status (Karnofsky PS ≤ 80% or 
ECOG PS ≥ 1) and the presence of visceral metastases [103]. Bajorin et al. showed that the 
mOS after treatment with MVAC differs between 9.1 and 33.0 months depending on the 
number of prognostic factors (see Figure 3a). These two potential prognostic factors have been 
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confirmed for both cisplatin-eligible and cisplatin-ineligible populations in several large trials 
using different platinum regimens [58, 66, 104]. 
For second-line treatment in mUC, it  has been suggested that ECOG PS > 1, the presence of 
liver metastasis, and low levels of haemoglobin (Hb < 10 g/dl) (referred to as the Bellmunt 
factors) are unfavourable prognostic markers [105]. In second-line treatment with vinflunine, 
the mOS differs from 1.7 to 14.2 months for patients with all three versus none of the suggested 
prognostic risk factors (see Figure 3b) [105]. 
 
Figure 3. Kaplan-Meier curves displaying different number of risk factors in first-line treatment with 
MVAC (Bajorin et al. 1999) (A) and second-line treatment with vinflunine (Bellmunt et al. 2010) (B). 
Reprinted with premission. © (1999 and 2010) American Society of Clinical Oncology. All rights 
reserved. 
 
There is further considerable heterogeneity in advanced UC with regard to de novo and 
acquired tumour resistance to the available systemic treatments. Molecular markers have the 
potential to personalise oncological treatment. Some promising candidate markers have been 
identified, but there are presently no biomarkers in use in clinical practice. Progress is being 
made in establishing a molecular classification for UC, which may prove to be a useful 
predictive molecular marker for different systemic treatments in the different stages of the UC 
disease [106, 107]. Alterations in DNA damage repair (DDR) genes may affect the response to 
platinum treatment and can potentially be valuable for analysis of patients with MIBC in the 
neoadjuvant setting , as well as to select chemotherapy or immunotherapy for patients with 
mUC [107, 108]. For immunotherapy, expression of PD-L1, mutations in DDR genes, tumour 
mutational burden, and microsatellite instability are possible molecular markers [109, 110]. 
Molecular markers and individualised treatment are addressed further in the Discussion 
(Chapter 5).  
 
1.5 ADVERSE EVENTS AND HEALTH-RELATED QUALITY OF LIFE 
Patients with mUC are often fragile due to severe disease-associated symptoms, comorbidity, 
and high average age, and thus they are susceptible to treatment-related toxicity. All of the 
widely used chemotherapeutical drugs for UC (cisplatin, carboplatin, gemcitabine, 
methotrexate, vinblastine, doxorubicin, paclitaxel, and vinflunine) are to different extents 
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associated with potentially severe side effects, as described above. Most common is 
haematological toxicity, which can be potentially dangerous or even fatal due to neutropenic 
sepsis or bleeding secondary to thrombocytopenia. Other common side effects that have a great 
impact on HRQoL are fatigue, nausea and vomiting, and loss of appetite, and for vinflunine 
also constipation and stomach pain. In general, ICIs have a more favourable toxicity profile 
than chemotherapy and therefore may be somewhat safer to administer in older patients and 
patients with poor PS. However, even if grade 3/4 AEs are less frequent with ICIs 
(approximately 10–20%) compared with chemotherapy, ICIs are also associated with the risk 
of irAEs (e.g., pneumonitis, thyroiditis, and colitis) that can be severe and even lethal [111]. 
In addition to assessing the toxicity profile related to treatment, it is important to measure the 
patients  HRQoL. Historically, research on HRQoL in UC has focused primarily on surgical 
procedures in MIBC patients, including complications of different urinary diversion techniques 
[112]. Data are more limited regarding HRQoL in patients with chemotherapy or other 
systemic medical treatments for MIBC and mUC [113]. For patients with MIBC, HRQoL seem 
to be inversely related to sexual function and urinary tract symptoms and increase six months 
after treatment. The impact of the neoadjuvant chemotherapy on HRQoL, however, is not 
studied separately from the influence of cystectomy [113]. In two large randomized clinical 
trials with first-line platinum chemotherapy in patients with mUC, HRQoL seemed to be stable 
or improve during the palliative chemotherapy compared to baseline measurements [36, 66], 
however the analyses were associated with low compliance and absence of bladder specific 
questionnaires. No studies have reported HRQoL data in RWD studies outside clinical trials 
for patients with MIBC or mUC [113]. The European Organisation for Research and Treatment 
of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) has been developed to 
assess the quality of life in cancer patients [114] and is the core instrument used in clinical trials 
in oncology to measure global health status, functioning (physical, emotional, cognitive and 
social), and common cancer-related symptoms [115]. At the onset of the present studies, no 

















The primary aim of this thesis was to improve chemotherapy in advanced urothelial cancer by 
investigating the recently introduced chemotherapeutical drug vinflunine in monotherapy and 
in novel treatment combinations, and to evaluate two different neoadjuvant chemotherapy 
regimens, with the overall goal of increasing survival and improving health-related quality of 
life (HRQoL). 
 
The specific aims of the present studies were as follows: 
 
Paper I 
• To evaluate treatment patterns, response rates, survival parameters, and adverse events 
of the novel vinca alkaloid vinflunine in patients with second-line metastatic urothelial 
cancer (mUC) in a routine clinical cohort (retrospective real-world data [RWD] study). 
• To investigate clinical prognostic factors for second-line treatment in mUC. 
Paper II 
• To examine safety and establish a recommended phase II dose for the novel 
combination of vinflunine and the antiangiogenic tyrosine kinase inhibitor sorafenib in 
second-line mUC patients (prospective dose-finding phase I trial). 
• To assess anti-tumour efficacy of vinflunine in combination with sorafenib. 
Paper III 
• To compare progression-free survival of treatment with the experimental combination 
of vinflunine and gemcitabine versus standard treatment with carboplatin and 
gemcitabine in first-line cisplatin-ineligible mUC patients (prospective randomised 
phase II trial). 
• To analyse response rates, overall survival, toxicity, and HRQoL in the experimental 
and control arms. 
Paper IV 
• To compare the pathological downstaging response to two different schedules of 
gemcitabine and cisplatin, a more cisplatin-dose-intense 3-week versus a 4-week 
schedule, as neoadjuvant chemotherapy prior to cystectomy in muscle-invasive bladder 
cancer (retrospective RWD study). 




3 PATIENTS, MATERIALS, AND METHODS  
 
An overview of the patients, materials, and methods in the four papers included in this thesis 




Table 1.  
Summary of patients, materials, and methods in the papers included this thesis 
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model by Ederer II  
RWD, real-world data; mUC, locally unresectable or metastatic urothelial cancer; MIBC, muscle-invasive 
bladder cancer; mOS, overall survival; MTD, maximum tolerated dose; RPTD, recommended phase II dose; 
mPFS, median progression-free survival; ORR, overall response rate; DCR, disease control rate; HRQoL, 
health-related quality of life; CT, computer tomography; MRI, magnetic resonance imaging; RECIST, 
Response Evaluation Criteria in Solid Tumours;  NCI-CTCAE v 4.0, National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.0; EORTC QLQ-C30, European Organisation for 
Research and Treatment of Cancer Quality of Life Questionnaire Core 30. 
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3.1 PATIENT COHORTS  
The patient cohorts in the four papers span over different stages of UC ranging from MIBC to 
first- and second-line treatment of mUC. The cohorts in Papers I–III comprised patients with 
non-curable unresectable (cT4b), locally advanced (N1–3), or metastatic (M1) urothelial 
carcinoma originating in the renal pelvic, ureter, urinary bladder, or urethra, defined as mUC. 
The patients in Papers I and II had progressed on first-line platinum chemotherapy and were 
treated with second-line chemotherapy. The population in Paper III consisted of patients 
treated with first-line chemotherapy who were ineligible for cisplatin due to renal impairment. 
We chose to exclude patients with ECOG PS ≥ 2, because tolerance for combination 
chemotherapy is known to be low in patients with both poor PS and impaired renal function 
[65]. 
Patients with curable MIBC (cT2–cT4aN0M0) were included in Paper IV. Patients with cT4b 
and/or suspected clinical lymph node metastases were excluded, because such patients are 
treated with an induction therapy approach that involves more extensive chemotherapy, and 
also involve different treatment outcome and prognosis [116]. 
The patients included in the four investigations were treated at oncological centres located in 
Sweden, Denmark, and Finland that are affiliated with the Nordic Urothelial Cancer Oncology 
Group (NUCOG). The participating centres in each study are listed in Appendix A. 
 
3.2 RETROSPECTIVE REAL-WORLD DATA STUDIES (PAPERS I + IV) 
In Paper I, the first 100 second-line mUC patients treated with vinflunine after the introduction 
of the drug in 2009 were analysed at three Nordic cancer centres affiliated with NUCOG. The 
patients were treated according to routine clinical practice until progression, unacceptable 
toxicity, or patient’s/physician’s decision to stop treatment. Data were collected from patient 
charts as stipulated in a prespecified questionnaire covering patient and disease characteristics, 
and prior treatment, vinflunine treatment, toxicity, and response and survival parameters (see 
Appendix B). The primary endpoint was overall survival defined as time from start of 
vinflunine treatment to all-cause death or date of last follow-up. Secondary endpoints included 
mPFS, ORR, DCR and toxicity and treatment patterns. Further analyses tested previously 
established clinical prognostic factors (ECOG PS, Hb, presence of visceral metastases and liver 
metastases), as well as potentially new clinical factors for mUC. 
The study reported in Paper IV included patients treated with two different schedules of 
gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy prior to cystectomy in MIBC at 
two centres in Sweden and five in Denmark. Both these countries apply similar guidelines for 
neoadjuvant chemotherapy, recommending treatment for patients with stage cT2–T4bN0M0, 
ECOG PS 0–1, GFR ≥ 50 ml/min, biological age ≤ 75 years, and no comorbidity contradicting 
chemotherapy or radical cystectomy. The patients were treated according to routine clinical 
praxis: in Denmark with four cycles of a 3-week schedule (GC-3w: cisplatin 70 mg/m2 day 1, 
gemcitabine 1000 mg/m2 days 1 and 8, q 21 days), and in Sweden with three cycles of a 4-week 
schedule (GC-4w: cisplatin at 70 mg/m2 day 1, gemcitabine 1000 mg/m2 days 1, 8 and 15, q 28 
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days). Information was collected from patient charts according to a prespecified questionnaire 
covering patient and disease characteristics, treatment patterns, side effects, and outcome 
measurements (see Appendix C). The primary endpoint was pathological complete response 
(pT0N0) and partial response (< pT2N0 = pT0N0, pTisN0, pTaN0, or pT1N0) at cystectomy. 
Secondary endpoints were relapse rate, survival parameters (from start of neoadjuvant 
chemotherapy to all-cause death, bladder-cancer-specific death, or date of relapse), toxicity,        
and treatment patterns. 
 
3.3 PROSPECTIVE CLINICAL TRIALS 
 
3.1.1 VINSOR – a dose-finding phase I trial (Paper II) 
The addition of sorafenib to vinflunine as second-line treatment in patients with mUC was 
investigated in the prospective clinical dose-finding phase I trial entitled VINSOR 
(ClinicalTrials.gov NCT01844947). Patients with disease relapse or progression no later than 
6 months after completion of previous platinum-combination treatment and with ECOG PS ≤ 1 
were eligible for inclusion. Patients with brain metastases, congestive heart failure, angina 
pectoris, poorly controlled hypertension, hypercalcaemia, hypokalaemia, prolonged QTc time, 
impaired bone marrow or liver function, or GFR < 40 ml/min at baseline were excluded. Three 
NUCOG centres participated in the trial. 
The study was performed according to a conventional 3 + 3 dose-escalation design with the 
primary endpoint to define the recommended phase II dose (RPTD) by evaluating toxicity 
[117]. Cohorts of three patients were added at each dose step and escalated to the next dose 
level depending on whether a dose-limiting toxicity (DLT) did or did not occur. The dose 
escalation continued until at least two patients in a cohort of three to six patients experienced 
DLTs (i.e., maximum tolerated dose [MTD]). The RPTD was defined as the dose of sorafenib 
and vinflunine one dose step below the MTD. A commonly used DLT definition was applied: 
grade ≥ 4 neutropenia (absolute neutrophil count < 0.5 x 109 for ≥ 7 days or < 0.1 x 109 for ≥ 3 
days); febrile neutropenia of grade ≥ 3 (absolute neutrophil count < 1.0 x 109 and temperature 
≥ 38.5 ˚C); thrombocytopenia of grade ≥ 4 or with bleeding or need of platelet transfusion; 
liver toxicity (ALAT/ASAT) grade ≥ 3 for > 7 days or any other major organ toxicity of grade 
≥ 3, if related to the study drugs and occurring during the two first treatment cycles. 
A fixed dose of vinflunine was administrated to all patients on day 1, q21 days, at either of the 
following levels: 320 mg/m2 if ECOG PS 0, age < 75 years, no previous radiation to the pelvic 
region, or GFR > 60 ml/min; or 280 mg/m2 if ECOG PS 1, age 75–80 years, previous radiation 
to the pelvic region, or GFR 40–60 ml/min. In addition, patients were prescribed daily sorafenib 
at a dose level of 400, 600, or 800 mg on days 2–21, escalating as described above. The patients 
were evaluated for toxicity weekly during cycle one and thereafter every third week. Treatment 
was continued until progression or unacceptable toxicity, or at the patient’s preference. The 





was performed according to the guidelines of Good Clinical Practice (GCP). The patient data 
were handled using the electronic Case Report Form (eCRF) system PheedIt. 
 
3.3.2 VINGEM – a randomised controlled phase II trial (Paper III) 
The randomised controlled clinical phase II trial designated VINGEM (ClinicalTrials.gov 
NCT02665039) compared vinflunine and gemcitabine (VG) with gemcitabine and carboplatin 
(GCa) as first-line treatment in cisplatin-ineligible patients with mUC. Patients with impaired 
renal function (GFR 30–60 ml/min), ECOG PS ≤ 1, and no prior chemotherapy for metastatic 
disease were included. Patients with impaired liver or bone marrow function, other 
malignancies, and any history of serious or concurrent illness or uncontrolled medical condition 
were excluded. Eleven centres associated with NUCOG participated in the trial. The patients 
were randomised 1:1 to the experimental arm VG (vinflunine 250 mg/m2 [age > 80 years and/or 
GFR 30–40 ml/min] or 280 mg/m2 [GFR 41–60 ml/min] on day 1 and gemcitabine 1000 mg/m2 
on days 1 and 8, q21 days) or to the control arm GCa (carboplatin area under the curve 4.5 
given on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8, q21 days). Treatment continued 
until unacceptable toxicity, progression, or patient’s choice to discontinue. Primary endpoint 
was mPFS, defined as time from randomisation to progression or death. Secondary endpoints 
were ORR, DCR, mOS, toxicity, and HRQoL. 
The VINGEM-trial was designed as a phase II screening trial [118] with mPFS as the primary 
endpoint, which implies that any eventual positive findings of the primary endpoint should be 
interpreted as a signal of effect. A definitive phase III trial would be necessary to confirm       
possible positive results. The trial was performed according to the guidelines of GCP. The 
patient data were handled using the eCRF system PheedIt. 
 
3.4 ADVERSE EVENTS AND HEALTH-RELATED QUALITY OF LIFE 
AEs were assessed with the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 4.0 (NCI-CTCAE v 4.0) [119]. For the retrospective studies (Papers 
I and IV), only grades 3 and 4 toxicity were reported. In the prospective clinical phase I and II 
trials (Papers II and III), all toxicity grades were reported using the eCRFs. Serious adverse 
events (SAEs) and suspected unexpected serious adverse reactions (SUSARs) in the clinical 
trials were reported to the sponsor according to the study protocols. Safety reports were 
submitted annually to the regulatory authorities and ethics committees in the participating 
countries according to applicable laws and regulations. 
In Paper III, HRQoL was measured at baseline and after every two treatment cycles, using 
EORTC QLQ-C30 [115] (see Appendix D). This questionnaire is composed of functional 
scales (global health status, physical functioning, role functioning, emotional functioning, 
cognitive functioning, and social functioning) and symptom scales/items (fatigue, nausea and 
vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, and diarrhoea). 
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3.5 ETHICAL AND MEDICAL APPROVALS 
Ethical approvals were obtained from the independent ethics committees in each of the 
participating countries for each study. Ethical and medical approvals are summarised in 
Appendix E. The prospective clinical trial VINSOR (Paper II) was approved by the Swedish 
and Danish medicine agencies and registered at ClincialTrials.gov (no. NCT01844947) and 
EudraCT (no. 2011-004289-14). The prospective clinical trial VINGEM (Paper III) was 
approved initially by the Voluntary Harmonisation Procedures (VHP) at European Medicines 
Agency (EMA) and subsequently by the national medicine agencies in Sweden, Denmark, and 
Finland. The VINGEM trial was registered at ClincialTrials.gov (no. NCT02665039) and 
EudraCT (no. 2013-002417-35), and further reported in accordance with the CONSORT 
guidelines for randomised controlled trials [120]. 
Patients in the prospective clinical trials (Papers II and III) were informed orally and in 
writing, and they provided written informed consent. The study participation was compliant 
with the Declaration of Helsinki [121], and the trials were performed in accordance with GCP, 
as well as with local laws and regulations. 
 
3.6 STATISTICAL ANALYSES  
Descriptive statistics was used to outline baseline characteristics, treatment patterns and safety. 
Differences in nominal data were assessed by the Pearson χ2-test and by Fisher’s exact test. P-
values < 0.05 were considered statically significant, except in HRQoL-analyses in which 
< 0.01 was used. IBM-SPSS statistics software for Windows (version 26; IBM, SPSS, Armonk, 
NY, USA) was used for most calculations in Papers I, II, and IV. In Paper III and for the 
survival analyses in Paper IV, the calculations were conducted using STATA software, 
version 15 (StataCorp LLC, College Station, TX, USA). 
 
3.6.1 Sample sizes 
The power calculation in Paper III showed that the study had to generate 110 PFS events to 
be able to detect a 50% increase in mPFS between the experimental and the control arm from 
5 to 7.5 months (hazard ratio [HR] of 0.67) with a one-sided significance level of 10% and a 
power of 80% (phase II screening trial [118]). Therefore, we decided to aim for a total of 120 
patients. Due to a slow accrual rate, an amendment was approved in April 2016, allowing the 
number of patients needed to be decreased to 60 based on a re-calculated power sampling (an 
increase in 80% in mPFS from 5 to 9 months [HR 0.56], α = 10% and β = 20%, generating 
56 PFS events). Randomisation was based on a permuted block technique and stratified for 
ECOG PS 0 versus ECOG PS 1 and for presence of visceral metastases versus no detected 
visceral metastases.  
For the dose-finding phase I trial outlined in Paper II, the sample size was determined 
depending on number of patients with DLT at each dose step, according to the protocol. A 
maximum of six patients were accrued at each dose level, and hence the maximum total accrual 
was 36 patients (18 patients for each vinflunine dose group). For the retrospective RWD studies 
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in Papers I and IV, all patients treated at the participating sites within a prespecified time 
period were included. 
 
3.6.2 Analyses of nominal data 
Nominal data were assessed using the Pearson χ2-test (Papers I and II) and Fisher’s exact test 
(Paper III), i.e., response measurements (ORR, DCR, complete response [CR], partial 
response [PR], stable disease [SD], and progressive disease [PD]), toxicity, and treatment 
patterns. In Paper IV, univariate regression analysis was used for the nominal primary 
endpoints (complete and partial pathological response), and for the secondary endpoints of 
treatment patterns and toxicity. Outcome was reported as odds ratio (OR) with 95% confidence 
interval (95% CI). Further, in Paper IV, multivariate logistic regression analyses were 
performed to adjust for baseline characteristic variables (calendar period, age, sex, ECOG, 
GFR, and clinical T stage), reported as adjusted OR (aOR) with 95% CI. 
 
3.6.3 Survival calculations 
In Papers I, II, and III, univariate analyses of time to event data (PFS and OS) were performed 
using the log-rank (Mantel-Cox) model. In Paper III, HRs were calculated using the Cox 
proportional hazard model, and efficacy (response and survival parameters) was evaluated 
according to the ITT principle including all participating patients and in the per-protocol 
population (i.e., excluding patients that completed less than one treatment cycle). To compare 
the relapse-free survival, bladder-cancer-specific survival, and OS in Paper IV, flexible 
parametric models were used to estimate the HR with 95% CI [122]. Adjusted hazard ratio 
(aHR) models included calendar period, age, sex, ECOG, GFR, and clinical T stage. 
In all four studies, the Kaplan-Meier method was used to illustrate the effect of treatment on 
survival and to estimate time-related measurements (including median and 5-year survival). 
However, in Paper IV, the imbalance in baseline characteristics led to heavily confounded 
Kaplan-Meier estimates. By using flexible parametric models that include the baseline 
parameters (calendar period, age, sex, ECOG, GFR, and clinical T stage), standardised survival 
curves were fitted, allowing the effect of treatment to vary over follow-up [122]. 
In Paper IV, we analysed survival more extensively by using the relative survival model. 
Relative survival measures the excess death due to bladder cancer (directly or indirectly due to 
the cancer diagnosis) in Sweden and Denmark, taking into account the different expected all-
cause mortality in the populations in the two countries, respectively [123]. Relative survival 
ratio was defined as the observed survival in the study cohort divided by the expected survival 
of a comparable group from the general population. Expected survival in the Danish and 
Swedish populations were estimated using the Ederer II method from Swedish and Danish 
population life tables, matched by age, sex, and year of chemotherapy start. The 5-year relative 
survival was defined as the ratio of the observed (patient) to the expected (population) survival 
using a cohort approach [124]. Crude and adjusted HR within 3 years from chemotherapy start 
were estimated using flexible parametric models [122]. 
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3.6.4 Health-related quality of life analyses 
In Paper III, the mean differences in HRQoL between the two treatment groups following two 
cycles of treatment, after controlling for baseline values, were analysed using linear regression 
models and scored with 99% CI using Walds test at a significance level of 0.01. The items in the 
questionnaire were linearly transformed to functioning or symptom scales ranging from 0 to 100 
according to the scoring manual [125]. Differences in scores were considered as small (S) if 5–9 







The results of the present studies, including the most important tables and figures, are provided 
in detail in Papers I–IV. The aim of this chapter is to give an overview of the main results, and 
additional complementary tables and figures are included here to further clarify the data from 
the studies or to highlight certain interesting findings. 
 
4.1 VINFLUNINE AS SECOND-LINE TREATMENT IN mUC (PAPER I) 
The RWD assessment reported in Paper I was performed to investigate the first 100 patients 
treated with the novel vinca alkaloid vinflunine. In summary, the mOS in our study was 
similar to data reported in the landmark randomised phase III trial comparing vinflunine with 
BSC [4]. The results of our study confirm that vinflunine is active as second-line treatment 
in an unselected routine clinical cohort of patients with mUC. However, there were large 
inter-individual differences in survival, ranging from 0.3 to 39.7 months. The ORR was 23%, 
and the DCR was 55%, and these values are higher than the results noted for vinflunine in 
the phase III trial. 
Patients treated outside well-defined clinical trials constitute a more heterogeneous cohort 
with regard to baseline characteristics and comorbidities. Twenty percent of the patients in 
Paper I presented with EOG PS 2 at baseline, whereas only patients with ECOG PS 0–1 
were  included in the phase III vinflunine trial [4]. Patients with ECOG PS 2 showed no CRs 
or PRs, 20% had SD, and 80% had PD. Furthermore, patients with ECOG PS 2 had shorter 
mOS (4.1 vs 7.0 months, P = 0.001) and a higher frequency of grade 3/4 toxicity (95% vs 
71%, P = 0.026) compared to patients with ECOG PS 0–1. Thus, based on our RWD, the 
clinical benefit of treatment with vinflunine in second-line for patients with ECOG PS ≥ 2 is 
questionable and cannot be recommended. 
We further explored clinical parameters that might be of prognostic value for survival in 
mUC. ECOG PS ≥ 2 and presence of visceral metastases were found to be prognostic adverse 
parameters, but we could not find any significant difference regarding Hb or liver metastases 
in our cohort of RWD patients. Patients with ECOG PS 0–1 and no visceral metastases had 
long mOS (18.1 months) compared to patients with one or two risk factors (ECOG PS ≥ 2 
and/or visceral metastases). 
Additional clinical parameters with potential prognostic correlation were also investigated 
and are summarised in Table 2. Response (CR or PR) to vinflunine treatment was a 
favourable factor for survival, and the same was noted for receiving six or more cycles of 
platinum chemotherapy prior to the start of vinflunine treatment. No other tested parameters 





Table 2.  





ECOG PS 0–1 vs 




No visceral metastases 




No liver metastases 




Hb ≥ 10 g/dl 




Response (CR + PR) 




≥ 6 cycles of platinum prior to vinflunine 




< 65 years old 




Start dose vinflunine 320 mg/m2 




No grade 3/4 AE 




Alkaline phosphatase normal 




Statistically significant differences are highlighted (P < 0.05). 
Above the dotted line are previously suggested prognostic factors for first- and 
second-line treatment, and below the line are other parameters tested for potential 
prognostic correlation. 
mOS, median overall survival; ECOG PS, Eastern Cooperative Oncology Group 
performance status; Hb, haemoglobin; CR, complete response; PR; partial 
response; SD, stable disease; PD, progressive disease; AE, adverse event. 
 
Grade 3/4 toxicity was high, with 76% of the patients experiencing at least one grade 3/4 AE. 
The most common grade 3/4 AEs were fatigue (36%), anaemia (33%), neutropenia (23%), 
and constipation (22%). Patients with ECOG PS 2, as compared to those with ECOG PS 0–
1, had a significantly higher degree of at least one grade 3/4 AE (95% vs 71%, P = 0.026) 
and fatigue (60 vs 30%, P = 0.012). There was no correlation between the presence or absence 
of at least one grade 3/4 AE and survival (Table 2). 
 
4.2 VINFLUNINE AND SORAFENIB AS SECOND-LINE TREATEMTENT IN 
mUC (PAPER II) 
VINSOR was a conventional 3+3 dose-escalation phase I trial, which was performed to 
examine the novel combination of vinflunine and sorafenib as second-line treatment in mUC. 
Twenty-two patients were included between April 2012 and September 2017. Nineteen patients 
were evaluable for toxicity according to the definition of DLT (see section 3.3.1). With 
vinflunine at 320 mg/m2, three DLTs occurred among the first five patients given sorafenib at 
the lowest dose level of 400 mg, and this combination was accordingly deemed too toxic for 
further evaluation (Figure 4). Treatment with vinflunine 280 mg/m2 reached the highest 
planned dose level together with sorafenib 800 mg, but three out of five patients experienced a 
DLT at that level-dose. Hence the MTD was determined to be the dose step below, that is, 
vinflunine 280 mg/m2 and sorafenib 600 mg, and therefore the RPTD was set at vinflunine 280 





Figure 4. Schematic overview of the dose escalation in the VINSOR trial (Paper II). Three patients were not 
evaluable as they received less than two cycles of treatment and did not experience any DLT. 
 
Toxicity was carefully monitored throughout the VINSOR trial. Overall, the toxicity profile 
concurred with previously described side effects for the two drugs given as monotherapy. All 
SAEs and AEs grade 1–5 are reported in Paper II. The most frequent AEs were fatigue (80%), 
constipation (60%), hypertension (47%), nausea (43%), and diarrhoea (42%). The most 
common treatment-related grade 3/4 AEs were neutropenia (32%), febrile neutropenia (26%), 
hypertension (16%), and hyponatraemia (16%). These AEs were most likely related to 
vinflunine [83], with the exception of hypertension, which has previously been described as a 
side effect of sorafenib [89]. The degree of hyponatraemia was higher than previously reported 
for vinflunine or sorafenib in monotherapy. The DLTs were febrile neutropenia (n = 5), 
neutropenia (n = 1), and hypertension (n = 1). 
Secondary endpoints in the VINSOR trial were ORR, mPFS, and mOS. Seventeen patients 
were evaluable for efficacy and survival. ORR was 41% (7 out of 17 patients), in all cases 
representing partial responses, and DCR (PR + SD) was 71% (12 out of 17 patients). Including 
all patients, the mPFS was 4.5 months (1.2–16.1 months), and mOS was 7.0 months (1.8–41.7 
months). 
 
4.3 VINFLUNINE AND GEMCITABINE AS FIRST LINE-TREATMENT IN mUC 
(Paper III) 
The randomised phase II trial VINGEM (Paper III) compared the experimental combination 
of vinflunine and gemcitabine (VG) with the standard carboplatin and gemcitabine (GCa) as 
first-line treatment in mUC patients ineligible for cisplatin. Sixty-two patients were included 
between April 2014 and February 2018 and were randomised to receive VG (n = 32) or GCa 
(n = 30). Assessments were conducted according to the ITT principle (n = 62) and also per-
protocol analysis (n = 59). Three patients in the VG arm did not receive any treatment specified 
in the protocol and hence were excluded from the per-protocol analysis. 
In the ITT analysis, the experimental combination VG did not improve the primary endpoint 
mPFS compared to standard treatment with GCa (median 6.2 vs 6.3 months [HR 0.75; 95% CI 
0.44–1.28; P = 0.293]). Furthermore, there was no significant difference in mOS between the 
two treatments (12.5 vs 10.6 months [P = 0.81]). Further, in the per-protocol analysis, there 
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was no significant difference in either mPFS or mOS between the two arms. Interestingly, ORR 
in the experimental arm VG was 63%, including 22% CR, and this level was significantly 
higher than in the GCa arm in the per-protocol analysis. Table 3 highlights the response data 
from Table 2 in Paper III. 
 
Overall, the side effects were manageable for treatment with VG and GCa. However, AEs were 
more frequently noted in the VG arm than in the control arm. The haematological toxicities, 
fatigue, gastrointestinal disorders, and nausea/vomiting were the most common treatment-
related AEs of all grades. The most common grade 3/4 AEs were neutropenia, 
thrombocytopenia, anaemia, febrile neutropenia, and infection. The VG arm displayed a high 
grade of grade 3/4 neutropenia (62% vs 43% in the GCa arm [P = 0.150]) and febrile 
neutropenia (31% vs 7% [P = 0.016]). One patient in the VG arm died due to febrile 
neutropenia (grade 5 AE). 
There were no statistically significant detectable differences in HRQoL between patients given 
VG and those receiving GCa (measured after two treatment cycles, i.e., at 7 weeks). However, 
moderate and small clinical differences favouring the GCa arm were found in several of the 
functional and symptom scales/items, see Figure 5. 
 
Table 3.  
Response rates in the intention-to-treat and per-protocol populations (Paper III) 
  Intention-to-treat    Per-protocola  
 Vinflunine/ 
gemcitabine            
n = 32 
Carboplatin/ 
gemcitabine            
n = 30 
P-value 
Vinflunine/ 
gemcitabine              
n = 29 
Carboplatin/    
gemcitabine                    
n = 30 
P-value 
Response       
    Complete response 7 (22) 1 (3) 0.054 7 (24) 1 (3) 0.026 
    Partial response 13b (41) 11 (37) 0.799 13b (45) 11 (37) 0.601 
    Stable disease 3 (9) 12 (40) 0.007 2 (7) 12 (40) 0.005 
    Progressive disease 5 (16) 6 (20) 0.746 5 (17) 6 (20) 1.000 
    Not evaluable 4 (13) 0 0.114 2 (7) 0 0.237 
       
Overall response rate  20b (63) 12 (40) 0.126 20b (69) 12 (40) 0.037 
Disease control rate 23b (72) 24 (80) 0.558 22b (76) 24 (80) 0.761 
Data are n (%). Statistically significant differences in response rates are highlighted (P < 0.05).                                                                                                                                       
aTwo patients were excluded due to adverse events before onset of treatment, and one patient was withdrawn 
due to infusion site reaction at first cycle.     




Figure 5. HRQoL at baseline and at 7 weeks (after two cycles) measured with EORTC QLQ-C30. 
Significance level at P ≤ 0.01. MD, mean difference (VG–GCa), baseline adjusted estimates. 
Differences in scores are considered to be small (S) if 5–9 points (marked in red) and as moderate (M) 
if 10–19 points (marked in blue). The functional scales (QL, global health status; PF, physical 
functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning; SF, social 
functioning) are presented above the dotted line, and the symptom scales/items (FA, fatigue; NV, nausea 
and vomiting; PA, pain;  DY, dyspnoea; SL, insomnia; AP, appetite loss; CO, constipation, DI, 
diarrhoea; FI, financial item) are shown below the dotted line. 
 
4.4 GEMCITABINE AND CISPLATIN IN MIBC (PAPER IV)  
Paper IV is a retrospective study of MIBC patients treated with neoadjuvant chemotherapy, 
which compared two separate GC schedules with different dose intensities and total doses of 
cisplatin and gemcitabine, and evaluated implications for efficacy and safety. Data were 
collected from a total of 706 patients, 251 treated with GC-4w at two centres in Stockholm, 
Sweden, and 455 treated with GC-3w at five centres in Denmark. The patients were treated 
between January 2010 and June 2018 in Sweden, and between January 2013 and June 2018 in 
Denmark. Adjustments for calendar period, age, sex, ECOG PS, GFR, and clinical T stage 
were made in the analyses of efficacy and safety due to imbalances in baseline characteristics. 
For the primary endpoint, the more cisplatin-dose-intense GC-3w schedule showed a 
significantly higher pathological response (pT0N0 and < pT2N0) compared to the GC-4w 
schedule. Complete response was achieved in 46% of the GC-3w patients compared to 32% of 
the GC-4w subjects (OR 1.85; 95% CI 1.33–2.57; P < 0.005). Corresponding values for 
downstaging to non-muscle-invasive disease were 60% and 47%, respectively (OR 1.67; 95% 
CI 1.21–2.29; P < 0.005). After adjusting for the imbalance in baseline characteristics, the 
significant difference in pT0N0 between the two schedules was still valid, but not for 
downstaging to < pT2N0. There were indications of an association with higher rates of 







Interestingly, despite the higher rate of pathological response with the three-week schedule, we 
did not find any overall, bladder-cancer-specific, or relapse-free survival advantage in patients 
treated with GC-3w compared to those given GC-4w. The Kaplan-Meier survival curves were 
adjusted for the imbalance in baseline characteristics, again showing no significant differences 
in survival. We further analysed excess death by considering differences in the background 
mortality in Sweden and Denmark. This sensitivity analysis did not either show any significant 
differences in survival between the two treatment groups, and it yielded survival curves that 
were similar to the Kaplan-Meier curves for bladder-cancer-specific survival. This 
contradictory finding, that the significantly higher proportion of complete responses did not 
translate into increased survival for patients treated with the GC-3w schedule, is given further 
consideration in the Discussion (Chapter 5). In the multivariate flexible parametric model, 
female sex and higher clinical stage were associated with poorer survival (Table 4). 
Figure 6 illustrates the hazards for bladder-cancer relapse, all-cause death, and bladder-cancer-
specific deaths. A notable observation is the high risk of relapse within the first two years after 
neoadjuvant chemotherapy, which translates into an increased risk of death within the first 
years after treatment. The median follow-up was shorter in the GC-3w group than in the GC-
4w patients (2.7 vs 3.6 years), and thus the hazard curves should be interpreted with caution 
after the third year. Furthermore, the time from relapse to death was unexpectedly short (6.2 
Table 4.  
Multivariable analysis of factors associated with pathological response and survival (Paper IV) 
 








 OR (95% CI)a OR (95% CI)a HR (95% CI)b HR (95% CI)b HR (95% CI)b 
Chemotherapy       
   GC-4w 1 1 1 1 1 
   GC-3w 1.74 (1.12–2.71) 1.05 (0.68–1.62) 1.32 (0.87–2.01) 1.26 (0.81–1.97) 1.25 (0.85–1.84) 
Calendar period      
   2010–2012 1 1 1 1 1 
   2013–2015 0.83 (0.47–1.48) 1.32 (0.75–2.32) 0.86 (0.52–1.40) 0.85 (0.50–1.43) 0.68 (0.44–1.07) 
   2016–2018 0.54 (0.29–0.98) 0.93 (0.52–1.68) 0.78 (0.46–1.33) 0.80 (0.45–1.40) 0.70 (0.44–1.13) 
Age interval      
   34–59 years 1 1 1 1 1 
   60–69 years 1.04 (0.70–1.56) 1.03 (0.69–1.54) 0.99 (0.68–1.45) 0.93 (0.62–1.38) 0.80 (0.57–1.14) 
   70–80 years 1.41 (0.90–2.22) 1.43 (0.91–2.26) 0.88 (0.57–1.36) 0.77 (0.48–1.23) 0.71 (0.47–1.05) 
Sex      
   Male 1 1 1 1 1 
   Female 0.92 (0.64–1.31) 0.71 (0.50–1.02) 1.62 (1.18–2.22) 1.73 (1.24–2.42) 1.73 (1.29–2.32) 
ECOG PS      
   0 1 1 1 1 1 
   1 0.71 (0.43–1.20) 0.60 (0.36–0.99) 1.22 (0.78–1.91) 1.21 (0.75–1.95) 1.26 (0.84–1.89) 
   Missing data 0.90 (0.45–1.81) 1.34 (0.63–2.81) 1.13 (0.60–2.13) 0.83 (0.38–1.80) 0.83 (0.42–1.66) 
GFR       
   < 70 ml/min 1 1 1 1 1 
   ≥ 70 ml/min 1.93 (1.16–3.20) 1.87 (1.16–3.01) 0.79 (0.52–1.18) 0.81 (0.52–1.25) 0.68 (0.47–0.99) 
cTNM      
   cT2N0 1 1 1 1 1 
   cT3N0 0.67 (0.43–1.03) 0.45 (0.29–0.69) 1.46 (1.00–2.16) 1.60 (1.06–2.43) 1.34 (0.93–1.91) 
   cT4N0 0.32 (0.13–0.83) 0.26 (0.11–0.59) 2.22 (1.23–3.99) 2.51 (1.35–4.64) 2.03 (1.18–3.51) 
   cTxN0 0.91 (0.60–1.36) 1.10 (0.72–1.67) 0.88 (0.58–1.34) 1.04 (0.67–1.63) 0.90 (0.60–1.34) 
Statistically significant differences are highlighted.  
aMultivariate logistic regression model. 
bMultivariate flexible parametric model. 
OR, odds ratio; CI, confidence interval; HR, hazard ratio; GC-4w,  gemcitabine and cisplatin 4-week schedule; GC-3w, 




months with the GC-4w schedule and 5.1 months with GC-3w), indicating a highly aggressive 
disease following relapse after initial cisplatin-based combination chemotherapy. 
 
Figure 6. Hazard curves for bladder-cancer relapse (A), all-cause death (B), and bladder-cancer death (C) 
for GC-4w versus GC-3w 
 
Side effects were manageable for both treatment schedules. A significantly higher degree of 
grade 3/4 neutropenia was seen in the GC-3w compared to GC-4w group (44% vs 36% 
[P = 0.032]), although this difference was not statistically significant after adjusting for the 
imbalance in the baseline characteristics. Accordingly, G-CSF was used significantly more 
often in the GC-3w than in the GC-4w treatment (27% vs 8% [P < 0.005]) in the unadjusted 
model but not in the adjusted model. No difference was observed between the two schedules 
with regard to frequency of febrile neutropenia. More patients with the GC-3w schedule 
terminated the treatment prematurely and experienced at least one dose delay, mainly due to 
neutropenia. Dose reduction and omitted doses were more common in the GC-4w than in the 
GC-3w group. Moreover, a particularly low dose intensity was seen for gemcitabine on day 15,     
where dose reduction occurred in at least one cycle in 30% and omitted dose in 47%, most 















In this chapter, the results of the present studies are discussed in a broader context and 
compared with published literature. The aim is to discuss chemotherapy in MIBC and mUC 
from a more general perspective in comparison with the current findings. Furthermore, several 
methodological concerns must be considered while interpreting our observations. 
 
5.1 METHODOLOGICAL CONSIDERATIONS 
 
5.1.1 Retrospective real-world data studies 
Randomised clinical trials are considered to be the gold standard in clinical oncological 
research. Nevertheless, RWD studies have the advantage of enabling analysis of more 
heterogeneous populations that more accurately reflect the real-world setting regarding        
aspects such as PS [126], comorbidities, and age. Moreover, RWD studies can provide data on 
subgroups, treatment sequences, and endpoints not included in clinical trial [127, 128]. The 
number of approved drugs and treatment options in advanced UC is rapidly increasing, thus it 
is of the utmost importance to use RWD to confirm the efficacy and safety of the novel 
treatment options in the real-life setting, as was done in the study outlined in Paper I. In a 
broader perspective, RWD can be utilised for health care decisions and estimations of cost 
effectiveness of the introduction of new drugs. An example of this is that the results reported 
in Paper I have been used as a comparator for the introduction of ICIs in second-line mUC in 
Sweden [129]. 
Retrospective RWD studies are limited in terms of the accuracy of the data collection, which 
leads to the risk of bias from several cofounders. In both Papers I and IV, there were a number 
of parameters that could not be controlled for. In those investigations, the clinical routines 
differed slightly between the participating centres with respect to staging procedures, health 
care management, and follow-up programmes, all of which might have had an impact on the 
evaluated efficacy parameters. For example, in Paper III, no information was recorded 
regarding surgical outcomes for pre-staging TUR-B and cystectomy (i.e., number of lymph 
nodes resected, positive surgical margins, and peri-operative morbidity and mortality) and 
oncological treatment after relapse, all important factors that might have influenced the survival 
outcomes in the study. In addition, data on other significant factors such as comorbidity burden, 
socio-economic factors, and smoking history were not included. Further, it is important to 
adjust for differences in baseline characteristics when comparing two different treatment 
options in a non-randomised study (Paper IV) in order to overcome the inevitable imbalance 
that occurs in routine cohorts. Still, there is a risk of bias from unknown cofounders despite 
careful adjustments. 
The assessment of toxicity in RWD studies is influenced by less frequent healthcare visits, and 
less accurate documentation of side effects compared to the meticulous reporting of side effects 
in clinical trials. Side effects of all grades may be underestimated, although grade 3 and 4 AEs 
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are more probably to be reported [128]. Further, efficacy data must be interpreted carefully due 
to lack of standardised assessments such as the use of Response Evaluation Criteria in Solid 
Tumours (RECIST) criteria or central assessment of pathological reports in ordinary clinical 
use. Nonetheless, in the study outlined in Paper I, the patients were subjected to a retrospective 
follow-up evaluation with RECIST, an approach that is not possible when studying larger 
cohorts. 
 
5.1.2 Prospective clinical trials 
Performing academic clinical trials is challenging in that it is associated with high costs and 
numerous regulatory formalities, and it is time consuming. In the rapidly evolving treatment 
landscape for mUC, the possibility to include patients in an ongoing trial can potentially change 
during the course of the study, as exemplified by the VINGEM trial, in which introduction of 
ICIs in first-line treatment made it more difficult to include patients (Paper III). Furthermore, 
there are limitations in accrual of first-line ineligible and second-line mUC patients in trials due 
to the rather limited number of patients with this diagnosis and the usually fragile patient 
populations, two aspects constituting a clear difficulty in both the VINSOR and the VINGEM 
trial (Papers II and III). 
Phase I dose-escalation trials aim to minimise the number of subjects exposed to unknown 
toxicity and maintain rapid accrual to identify the MTD of the experimental drug or the novel 
drug combination. Further, phase II and III trials are necessary to evaluate the efficacy of the 
novel drug or drug combination. Therefore, the efficacy data that are described regarding the 
VINSOR trial (Paper II) are merely descriptive. 
VINGEM (Paper III) was designed as a phase II screening trial with the primary endpoint 
mPFS [118], and thus any positive results should be interpreted as a signal of effect and must 
be confirmed in a definitive phase III trial. The main limitation of VINGEM was that it had to 
be downsized from 120 to 60 patients due to a slow accrual rate, which reduced the statistical 
power and the possibility to detect statistically significant differences between the two 
treatment arms. 
 
5.2 NEOADJUVANT TREATMENT IN MIBC 
Cisplatin-based neoadjuvant chemotherapy prior to cystectomy improves survival in patients 
with MIBC, but the optimal neoadjuvant regimen still remains unknown. No randomised 
clinical phase III trials comparing different regimens have yet been finally reported, although 
in France there is an ongoing randomised phase III trial (VESPER) comparing dd-MVAC with 
a 3-week schedule of GC, and it is expected that the final results of this study will be presented 
in mid 2021 [130]. In the study described in Paper IV, we found that a more cisplatin-dose-
intense 3-week schedule of GC, as compared to a commonly used 4-week schedule, was 
associated with significantly higher rates of pathological complete response (pT0N0) and 
downstaging to non-muscle-invasive disease (<pT2N0). The pathological response rates for 
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the two schedules were in the same range or exceeded numbers reported in the literature from 
other neoadjuvant trials using different cisplatin-based regimens [38-41, 44, 45]. 
Downstaging to pT0N0 or < pT2N0 has been suggested as a surrogate marker for survival 
following neoadjuvant treatment in patients with MIBC [49, 50]. Notably, despite the higher 
rate of pathological response in patients treated with GC-3w compared to those with GC-4w in 
Paper IV, no significant differences in survival outcomes could be detected between the two 
schedules. This peculiar finding indicates that, in addition to downsizing the primary tumour 
in the bladder, an important role of neoadjuvant chemotherapy is to eradicate distant micro-
metastases. Approximately one third of the patients in our study did relapse, with no significant 
difference between GC-3w and GC-4w, indicating possible heterogeneity in cisplatin-
sensitivity between tumour cells of the primary tumour in the bladder and circulating micro-
metastases. To circumvent the cisplatin resistance, it appears to be important to combine 
cisplatin with drugs with different mechanisms of action rather than to further increase the dose 
and intensity of the cisplatin-based chemotherapy. 
Patients with residual tumour (≥ pT2N0 and/or node-positive disease) after neoadjuvant 
chemotherapy have a poor prognosis; in Paper IV, the 5-year survival for such patients was 
only 45% compared to 90% for those with pT0N0. In line with perioperative treatment in other 
cancer diagnoses (e.g., breast cancer [131]), both neoadjuvant and adjuvant treatment might be 
of value for selected patients. To address that issue, better response assessments are needed to 
individualise the treatment. Measuring circulating tumour DNA (ctDNA) after neoadjuvant 
chemotherapy and cystectomy is one possible strategy that might enable selection of patients 
that may benefit from additional adjuvant treatment, preferable with drugs with different 
mechanisms of action than platinum-compounds [132, 133]. 
 
5.3 FIRST-LINE TREATMENT IN mUC  
Cisplatin combination chemotherapy is the treatment of choice in first-line mUC. However, 
approximately half of mUC patients are not eligible for cisplatin, and the ineligible population 
shows inferior survival compared to eligible mUC patients given cisplatin-based treatment. In 
the randomised phase II trial VINGEM (Paper III), we explored vinflunine in combination 
with gemcitabine in patients ineligible for cisplatin due to renal impairment. No statistical 
differences in mPFS or mOS were seen between VG and the control arm GCa, although the 
experimental arm with VG did show a notably high frequency of responses. The ORR for 
patients treated with VG exceeds the numbers reported from other trials with cisplatin-
ineligible patients and is comparable to the best response data reported for all systemic 
treatments in mUC (see Table 5). The ORR of 63% makes VG a promising treatment option, 
but this novel combination must be further explored in larger trials with mUC patients. Also, 
the VG combination would be interesting to investigate as neoadjuvant treatment for MIBC 
patients with renal impairment, for whom no treatment options are presently available, to 




Patients that are cisplatin-ineligible are heterogeneous, and different criteria for being unfit 
have been used. In the VINGEM trial (Paper III), impaired renal function was the only 
criterion applied to define cisplatin ineligibility, which constitutes a homogeneous patient 
cohort. Other trials have included patients with various parameters for being cisplatin ineligible 
(e.g., impaired renal function, ECOG PS 2, congestive heart failure, impaired hearing, and 
peripheral neuropathy) (Table 5), which reduces the possibility of cross-study comparison. The 
VG combination was also evaluated in the JASINT1 trial [75], which used the same definition 
for unfit as applied in the VINGEM trial, and the outcome data in these two trials were similar 
regarding efficacy and toxicity. Only one randomised phase III trial with cisplatin-ineligible 
patients (M-CAVI compared to GCa) has been performed [65, 66], and, in that investigation, 
patients with two criteria for being unfit for cisplatin (ECOG PS 2 and GFR 30–60 ml/min) 
showed a low response rate, short mOS, and a high degree of AEs. It seems that patients with 
both renal impairment and poor PS do not benefit from combination chemotherapy and should 
be considered for mono-chemotherapy, drugs with alternative mechanisms of action, inclusion 
in clinical trials, or BSC. 
In the single-arm phase II trials for treatment with ICIs in first-line cisplatin-ineligible patients 
[67, 69], the majority of patients were ineligible to cisplatin due to renal impairment, but 
patients with ECOG PS 2, heart failure, peripheral neuropathy, and hearing loss were also 
Table 5.  















First-line cisplatin-eligible patients 





72 36 NR 14.8  
Sternberg et al. 





64 vs 50 21 vs 9 9.5 vs 8.1 15.1 vs 14.9  
von der Maase et al. 
2000, 2005 [36, 58] 
GC vs MVAC 
Randomised 
phase III 
49 vs 46 12 vs 12 7.7 vs 8.3 14.0 vs 15.2  
Bellmunt et al. 
2012 [62] 
PCG vs GC 
Randomised 
phase III 
56 vs 44 14 vs 11 8.3 vs 7.6 15.8 vs 12.7  
First-line cisplatin-ineligible patients 
Criteria for 
“unfit” 
Holmsten et al.  
2019 (Paper III)  
VG vs GCa 
Randomised 
phase II 
63 vs 40 22 vs 3 6.2 vs 6.3 12.5 vs 10.6 GFR 30–60  
De Santis et al. 
2016 [75] 
VG vs VCa 
Randomised 
phase II 
44 vs 28 6 vs 11 5.9 vs 6.1 14.0 vs 12.8 GFR 30–60  
De Santis et al. 





41 vs 30 3 vs 3 5.8 vs 4.2 9.3 vs 8.1 
GFR 30–60  
ECOG PS 2 
Balar et al. 
2017 [67]  





29 9 NR 11.3 
GFR 30–60  




Heart failure  






23 9 2.7 15.9 
GFR 30–60 




aAt least one of the following criteria. 
The response rates in the VINGEM trial (Holmsten et al.) are highlighted for comparison. 
ORR, overall response rate; CR, complete response; mPFS, median progression-free survival; mOS, median overall survival;  MVAC, 
methotrexate, vinblastine, doxorubicin, and cisplatin; HD-MVAC, high-dose MVAC; GC, gemcitabine and cisplatin; PCG, paclitaxel, 
cisplatin, and gemcitabine; VG, vinflunine and gemcitabine; GCa, gemcitabine and carboplatin; GFR, glomerular filtration rate, ml/min; 
M-CAVI, methotrexate, carboplatin, and vinblastine;  ECOG PS, Eastern Cooperative Oncology Group performance status; VCa, 
vinflunine and carboplatin; NR, not reported. 
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included. Two large ongoing trials including both cisplatin-eligible and ineligible patients in 
first-line treatment are assessing ICIs in monotherapy in comparison with ICIs combined with 
chemotherapy and chemotherapy alone [134, 135]. These trials will provide important 
information about the benefit of the available treatment options in first-line mUC. Hopefully, 
additional knowledge will also be obtained about the efficacy and safety profile of ICIs and 
carboplatin-combination chemotherapy in the different subgroups within the cisplatin-
ineligible population 
The toxicity profile is well known for cisplatin and carboplatin combinations and is illustrated         
schematically in Table 6. The side effects in the experimental arm VG in the VINGEM trial 
(Paper III) were reasonable, although a higher degree of AEs were reported for VG than for 
standard GCa. The high degree of neutropenia and febrile neutropenia observed in the VG arm 
is of special concern and was higher than reported for treatment with VG in the JASINT1 trial 
[75]. However, the start dose of gemcitabine was lower in the JASINT1-trial, which may partly 
explain the observed differences. Given the high frequency of neutropenia and associated 
febrile neutropenia for VG in the VINGEM trial, adjusted doses or treatment with G-CSF may 

















5.4 SECOND-LINE TREATMENT AND BEYOND IN mUC  
At the time the present thesis was initiated, vinflunine had recently been introduced in routine 
clinical practice as standard second-line treatment after progression on platinum chemotherapy. 
As the survival advantage with vinflunine is small (2.6 months in comparison with BSC) [4], 
and the toxicity profile of this drug may be a concern, especially regarding constipation and 
neutropenia,  it is clearly important to evaluate vinflunine in an unselected clinical routine 
cohort. In Paper I, we confirmed that vinflunine is an active drug in everyday clinical use, with 
mOS and side effects comparable to those reported in the landmark phase III trial of vinflunine 
[4]. Furthermore, the results in Paper I agree with other RWD studies of vinflunine that have 
Table 6. 








Anaemia     
≥ 55% 
Neutropeniad     
Febrile neutropeniae     
30–54% 
Thrombocytopenia     
Infection     
10–29% 
Fatigue     
Nausea/vomiting     
< 10% 
Constipation     
aHolmsten et al. 2019 (Paper III), De Santis et al. 2016 [75]. 
bHolmsten et al. 2019 (Paper III), De Santis et al. 2012 [66]. 
cGC and MVAC, von der Maase et al. 2000 [36]; PCG, Bellmunt et al. 2012 [62]. 
dFor vinflunine/gemcitabine, very high in Holmsten et al. 2019, high in de Santis et al. 2016. 
eFor vinflunine/gemcitabine, high in Holmsten et al. 2019, low in de Santis et al. 2016. 
GC, gemcitabine and cisplatin; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; PCG, 
paclitaxel, cisplatin, and gemcitabine. 
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been published after our trial was conducted [128, 136]. Vinflunine has also been included as 
the control arm (investigators’ choice of vinflunine, paclitaxel, or docetaxel) in the randomised 
phase III trials for pembrolizumab and atezolizumab in second-line treatment [94, 95]. In the 
atezolizumab trial, the mOS for patients treated with vinflunine was 8.3 months, which was 
longer than expected based on previous investigations. Efficacy data from selected studies of 
second-line treatment are presented in Table 7 for comparison with the findings in Paper I. In 
summary, data from both randomised trials and RWD confirm the role of vinflunine as an 
active option for treatment of platinum-resistant mUC patients. 
 
Table 7. 
Response and survival in second-line treatment 







Holmsten et al. 




23 2.8 6.3 
Shah et al.  





41 4.5 7.0 
Bellmunt et al.  
2009 [4] 




9 vs 0 3.0 vs 1.5 6.9 vs 4.3 






19 2.3 to 6.2 5.2 to 11.9 






21 vs 11 2.1 vs 3.3 10.3 vs 7.4 






13 vs 13b 2.1 vs 4.0b 
8.6 vs 8.0b 
8.3 for vinflunine 
aInvestigators’ choice of vinflunine, docetaxel, or paclitaxel. 
bIn the intention-to-treat population. 
The OS for the RWD trial of vinflunine (Holmsten et al.) and the ORR from the VINSOR trial (Shah et 
al.) are highlighted for comparison. 
ORR, overall response rate; mPFS, median progression-free survival; mOS, median overall survival; 
RWD, real-world data; BSC, best supportive care. 
 
The approval of ICIs in 2017 introduced a new approach with a principally different 
mechanism of action in mUC patients progressing on platinum treatment. Furthermore, the 
fibroblast growth factor receptor (FGFR) inhibitor erdafitinib [137] and the antibody-drug 
conjugate (ADC) targeting Nectin-4 enfortumab vedotin [138] were recently approved by the 
FDA for treatment in second line or beyond. Intense research is also ongoing to investigate 
chemotherapy in combination with drugs with different mechanisms of action to improve 
response and survival in platinum-resistant mUC patients. In the phase I trial VINSOR (Paper 
II), we show that the novel treatment combination of vinflunine and the antiangiogenic VEGFR 
multi-tyrosine kinase inhibitor sorafenib offers a tolerable and safe treatment. The reported 
ORR, mPFS, and mOS are shown in Table 8, and the observed ORR of 41% and DCR of 71% 
are notable and exceed the corresponding numbers noted in other second-line trials. The higher 
response rate might be attributed to the addition of sorafenib, or perhaps simply to chance 
considering the limited sample size; phase I trials are not designed to evaluate efficacy 
parameters. In comparison, a randomised phase II trial assessing GC plus sorafenib or GC alone 
in first-line treatment showed no additional response or survival effect of sorafenib [139]. Also, 
another VEGFR antagonist, ramucirumab, has been observed to have initial promising effects 
in platinum-refractory mUC patients, with improved mPFS in combination with docetaxel 
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compared to docetaxel alone, although this did not translate into prolonged survival in patients 
receiving ramucirumab [140, 141]. Treatment strategies targeting angiogenesis, including trials 
with vinflunine in combination with sorafenib may be further explored in selected patients. 
Treating patients in second or third-line and beyond in mUC is a medical challenge, since a 
considerable proportion of the patients present with a large tumour burden and multiple 
tumour-associated symptoms. Moreover, patients in late-stage disease often present with an 
overall poor PS which  makes them more susceptible to side effects of systemic treatments. In 
Paper I, patients with ECOG PS 2 showed less efficacy of vinflunine treatment and more side 
effects. Patients with ECOG PS ≥ 2 are generally excluded from clinical trials [126], which 
was also the case in the randomised phase III trials of vinflunine [4], pembrolizumab [95], and 
atezolizumab [94] in second-line mUC, as well as in the single-arm phase II trials with 
enfortumab vedotin in third-line mUC [138] and erdafitinib in second-line mUC [137]. The 
impact of poor performance status in treatment with ICIs remains unknown, although a recent 
retrospective RWD study indicated that patients with ECOG PS ≥ 2 show similar survival as 
those with ECOG PS 0–1 in second-line treatment [142]. The clinical benefit of systemic 
treatment in second-line or beyond for mUC patients with ECOG PS ≥ 2 is questionable in 
light of the today present knowledge, and patients should be treated with caution and 
preferably, if possible, within clinical trials. 
 
5.5 PROGNOSTIC CLINICAL FACTORS AND MOLECULAR MARKERS 
Patients with late stage mUC are highly heterogeneous regarding both clinical characteristics 
and sensitivity to the administered treatment drug. There is an urgent need for validated clinical 
and molecular prognostic and predictive markers to enable better individualisation of the 
treatment. For chemotherapy in mUC, prognostic clinical factors for survival are established 
for first- and second-line treatment [103, 105]. In Paper I, we evaluated the proposed 
prognostic parameters for mUC and confirmed that poor PS and the presence of visceral 
metastases were associated with shorter survival. Clinical prognostic factors for treatment of 
ICIs are still unknown, although a recent study suggested a five-factor model that correlates 
with survival, including ECOG PS > 1, presence of liver metastases, platelet count, neutrophil-
lymphocyte ratio, and serum lactate dehydrogenase [143]. 
Extensive research is in progress regarding molecular markers associated with the efficacy of 
chemotherapy in UC. It is possible that the establishment of a molecular classification can aid 
selection of patients that are suitable for chemotherapy, as well as for ICIs and targeted therapy. 
For example, patients with basal differentiation appear to benefit from cisplatin-based 
chemotherapy and ICIs, whereas patients in the subgroup of “luminal infiltrated” do not seem 
to benefit from chemotherapy but from ICIs. FGFR is overexpressed in the “luminal-papillary” 
subgroup, and patients in that category are likely to benefit from FGFR inhibitors such as 
erdafitinib [22, 25]. Also, alterations in DDR genes have been associated with response to 
platinum-based chemotherapy in MIBC and mUC [144, 145], although further studies are 
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required to determine whether DDR genes can serve as a reliable molecular marker in UC 
[107]. 
The responses to ICIs are usually durable. However, only approximately 15–25% of the 
patients with mUC do respond to such treatment, which highlights the need for molecular 
markers to select patients that will benefit from immunotherapy. The expression of PD-L1 has 
been suggested as a predictive biomarker, but its significance in advanced UC is still unclear 
[24, 110]. Extensive research is in progress to identify potential molecular markers for ICIs, 
such as mutations in DDR genes, tumour mutational burden, and microsatellite instability, 
although the accuracy and robustness of possible markers must be further evaluated and tested 
in prospective clinical trials [24, 110, 146, 147]. 
 
5.6 ADVERSE EVENTS AND HEALTH-RELATED QUALITY OF LIFE  
In the search for more effective drugs or treatment combinations in cancer care, side effects 
and HRQoL must always be taken into consideration. Higher doses of chemotherapy or more 
dose-intense treatment usually results in better tumour control but at the price of more toxicity, 
and hence it is a question of achieving a balance between efficacy of the treatment regimen and 
the toxicity profile. A higher degree of side effects is usually accepted for patients with MIBC 
given curative neoadjuvant treatment prior to radical cystectomy than for patients with mUC 
in the palliative setting for whom HRQoL during the remainder of life is of primary importance. 
HRQoL assessment is a valuable instrument to more accurately investigate how the disease 
and side effects of the cancer treatment influence the patients in everyday life. Nonetheless, 
data are limited regarding HRQoL in relation to systemic treatment in UC [113]. The sparse 
knowledge available today stems primarily from patients in clinical trials that represent highly 
selected populations, and data on HRQoL from RWD studies are limited. Furthermore, 
information is usually obtained using general questionnaires such as the EORTC QLQ-C30 
and not cancer-diagnosis-specific questionnaires. This was also the case for the HRQoL 
analyses in the VINGEM trial (Paper III), in which no significant differences in HRQoL were 
observed between the treatment arms. However, small and moderate clinical differences in 
favour of the control arm GCa were noted in that trial, which were probably related to the 
overall higher frequency of all grades of AEs reported for the experimental arm VG. After 
initiation of the VINGEM trial, both a diagnosis-specific questionnaire for MIBC (QLQ-
BLM30) and a cross-diagnostic questionnaire for HRQoL in palliative cancer care patients 
(QLQ-C15-PAL) were developed [114]. Addition of these questionnaires to the basic QLQ-
C30 in the VINGEM trial probably would have provided further important information that 
might have better reflected the HRQoL of the included patients. 
For patients treated with chemotherapy for various metastatic solid tumours, it has been noted 
that the use of patient-reported outcomes (PROs) in addition to routine clinical visits are 
significantly associated with increased survival as compared to usual outpatient care alone 
[148]. Improving symptom management by use of PROs can also lead to better HRQoL, less 
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frequent admissions to the hospital, and that patients can remain on chemotherapy longer [149]. 
Disease-specific PRO items for mUC patients were recently suggested [150]. Still, much 
remains to be determined about how different treatments affect HRQoL in advanced UC [113], 
and future prospective clinical trials should preferably include HRQoL assessment with 










































• Vinflunine was confirmed to be an active drug as second-line treatment in a routine 
clinical cohort of patients with metastatic urothelial cancer (mUC). 
• Poor performance status and the presence of visceral metastasis were negative clinical 
prognostic factors for vinflunine treatment. 
• Patients with ECOG PS 2 showed a short overall survival and a high degree of severe 
toxicity. 
Paper II 
• Vinflunine and sorafenib could be safely combined for treatment of second-line mUC 
patients, and a recommended phase II dose was identified. 
• The most common dose-limiting toxicity was febrile neutropenia. 
• The novel combination of vinflunine and sorafenib generated clinically meaningful 
disease stabilisation and tumour responses. 
Paper III 
• Vinflunine and gemcitabine (VG) did not improve the progression-free survival 
compared to standard treatment with gemcitabine and carboplatin as first-line treatment 
in cisplatin-ineligible patients with mUC. 
• The experimental combination of VG showed a high overall response rate including a 
notably high degree of complete responses. 
• The VG combination was generally tolerable, albeit with a high degree of neutropenia 
and febrile neutropenia. No differences in health-related quality of life were observed 
between the two treatment arms.   
Paper IV 
• Gemcitabine plus cisplatin given as a more cisplatin-dose-intense 3-week schedule 
compared to a commonly used 4-week schedule in muscle muscle-invasive bladder 
cancer resulted in significant differences in pathological response rates in favour of the 
3-week schedule. 
• No differences in survival were seen between the two schedules. 
• The toxicity profile was manageable in both schedules, but more neutropenia and 








7 FUTURE PERSPECTIVES 
This thesis is focused on treatment efficacy, safety and HRQoL in patients undergoing 
chemotherapy for advanced UC. Until recently, chemotherapy was the only option for systemic 
treatment of patients with advanced UC. Increased knowledge of the biology of UC and the 
introduction of immunotherapy have dramatically altered the clinical management of this 
disease over the past years. Extensive research is ongoing with several novel drugs, including 
ICIs, drugs targeting angiogenesis, tyrosine kinase inhibitors (e.g., FGFR inhibitors), and ADC 
[151]. Furthermore, numerous trials are evaluating combinations of these drugs in different 
stages of UC. At present, more than 200 clinical trials are ongoing that are focused on advanced 
UC [152]. The FGFR inhibitor erdafitinib [137] and the ADC enfortumab vedotin [138] were 
recently approved by the FDA for treatment in second-line or beyond, and it is expected that 
these  drugs will soon be available for clinical use in Europe and Sweden. Even though the 
introduction of ICIs and targeted therapies represents a major  breakthrough in the treatment of 
patients with mUC, the response rates and OS are still limited [67, 69, 94-96, 137, 138]. 
Accordingly, chemotherapy is likely to remain a cornerstone in systemic oncological treatment 
of advanced UC for the foreseeable future. 
Despite the rapidly evolving treatment landscape for patients with mUC, there is still a need to 
further improve existing and develop new chemotherapy-based treatment regimens. The novel 
combination of VG, explored in the randomised phase II trial VINGEM (Paper III), shows 
promise as first-line treatment in mUC patients with impaired renal function, and it has a 
notably high ORR. This combination merits further evaluation in mUC patients and might also 
be of interest to investigate as neoadjuvant treatment in cisplatin-ineligible MIBC patients with 
renal impairment, a group that currently lacks treatment options. In the future, it is possible that 
mUC patients who are ineligible for cisplatin can achieve OS similar to that reached in 
cisplatin-eligible patients by applying new treatment options such as VG or combinations of 
chemotherapy and drugs with different mechanisms of action in individualised treatment 
strategies. Recently, drugs targeting angiogenesis and the VEGF pathway have been explored 
in mUC [139, 141, 151]. The combination of vinflunine and the antiangiogenic multi-tyrosine 
kinase inhibitor sorafenib can be safely administered, as shown in the VINSOR trial (Paper 
II). The next step is to further evaluate this novel combination in a phase II trial to assess 
efficacy and survival compared to standard second-line treatment in mUC. In accordance with 
this approach, other trials targeting angiogenesis in combination with chemotherapy or ICIs are 
in progress and may be an effective treatment alternative for selected patients. 
As the number of available treatment options increases in mUC, there is an urgent need to 
develop biomarker-driven precision medicine approaches to optimise treatment selection and 
sequencing for the individual patient. For cisplatin, promising treatment-predictive biomarkers 
are evolving, such as DDR genes and molecular classification [107], although no validated 
markers have yet been established for routine clinical use. Considering vinflunine, no 
biomarkers have been investigated in the clinical setting. Blood samples have been          
collected from patients in the VINGEM trial (Paper III) to enable future studies on biomarker 
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profiling aimed at exploring molecules involved in the cytotoxic mechanisms of action for 
vinca alkaloids [153, 154]. 
In patients with MIBC, neoadjuvant cisplatin-based chemotherapy is undoubtedly effective in 
achieving pathological downstaging of the primary tumour in the bladder (Paper IV), although 
approximately one third of the patients do relapse. Initial small single-arm studies with ICIs in 
the neoadjuvant setting show promising results [51, 52], and a large number of ongoing trials 
are evaluating ICIs and targeted drugs in monotherapy or in combination with chemotherapy 
in patients with MIBC [5, 155]. Patients with remaining residual tumour in the bladder after 
neoadjuvant chemotherapy constitute a high-risk population with poor prognosis. Future 
research should focus on additional adjuvant systemic therapy after neoadjuvant chemotherapy 
and cystectomy for selected patients [156-158], preferably considering drugs with different 
mechanisms of action and based on the molecular profile of the residual tumour in the 
cystectomy specimen. Furthermore, neoadjuvant chemotherapy presently in use excludes 
patients that are cisplatin-ineligible, and the current standard of care is cystectomy alone. In 
cisplatin-unfit patients with MIBC, ICIs are also being explored [34, 155], although other 
potential treatment options should be investigated as well, for example, using vinflunine 
together with gemcitabine (Paper III) or vinflunine as the backbone in combinations with non-
nephrotoxic drugs with different mechanisms of actions. 
The neoadjuvant setting for patients with MIBC is suitable for evaluating signals of activity 
with new agents and novel treatment combinations by assessing the tumour response in the 
cystectomy specimen.  In addition, longitudinal tumour sampling from pre-treatment TUR-B 
and post-treatment cystectomy is easily accessible, which enables analyses of treatment-
induced molecular changes that may serve as biomarkers. There are currently no available 
biomarkers to distinguish MIBC patients that are de novo resistant to cisplatin treatment. 
Moreover, approximately 10% of patients that achieve complete response do relapse, indicating 
possible heterogeneity in the sensitivity of tumour cells to cisplatin in the primary tumour in 
the bladder and in circulating micro-metastases. Future neoadjuvant studies should include a 
precision medicine approach aimed at selecting patients likely to benefit from neoadjuvant 
cisplatin-combination chemotherapy based on molecular profiling. 
Advanced UC is a disease associated with high morbidity, and especially patients in late stage 
mUC often present with multiple tumour-associated symptoms and overall poor PS. 
Furthermore, the toxicity profiles of the chemotherapy regimens available today are all to 
different extents associated with more or less severe side effects. In addition to the development 
of more effective treatment options, future clinical trials should focus not only on measurement 
of efficacy endpoints like response and survival, but also on more direct evidence of clinical 
benefit for the patients, such as relief of tumour-related symptoms, increased physical 
functioning, and improved HRQoL, for this severely ill patient population.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Cancer i urinblåsan är den sjunde vanligaste cancerformen i Sverige med drygt 3000 fall per 
år. Sjukdomen delas in i tre stadier: 1) ytlig urinblåsecancer som begränsar sig till inne i 
urinblåsan och har god prognos, 2) avancerad sjukdom som går djupare in i muskellagret i 
urinblåsan (muskelinvasiv sjukdom) och 3) metastaserad sjukdom där tumören har spridit sig 
ut i kroppen, vanligtvis till lymfkörtlar, lever, lungor eller skelettet. Muskelinvasiv och 
metastaserad urinblåsecancer är aggressiva sjukdomar som kan ge upphov till många 
tumörrelaterade symtom och har hög dödlighet. För patienter med metastaserad sjukdom är 
överlevnaden i medeltal endast cirka 15 månader. Behovet av att utveckla nya effektivare 
behandlingsalternativ är således mycket stort.  
Standardbehandling för muskelinvasiv urinblåsecancer är cytostatika (”cellgifter”) följt av 
bortoperation av urinblåsan. Trots intensiv behandling så drabbas knappt hälften av 
patienterna av återfall i form av antingen lokal tumörväxt i lilla bäckenet eller av metastaser, 
varvid sjukdomen inte längre är botbar. För patienter med metastaserad urinblåsecancer är 
bromsande behandling med platinum-innehållande cytostatikakombinationer (cisplatin eller 
karboplatin) standardbehandling sedan slutet av 80-talet. Vinflunine introducerades 2009 
som det första nya läkemedlet på flera decennier, och tillför en begränsad men viktig 
överlevnadsvinst för patienter som inte längre har effekt av platinumbehandling. 
Immunterapi har medfört ett stort genombrott i behandlingen av många cancertyper, och så 
även för urinblåsecancer där immunterapi godkändes 2017 för behandling av patienter med 
metastaserad sjukdom. 
Syftet med denna doktorsavhandling var att förbättra behandlingen med cytostatika i olika 
faser av urinblåsecancer, med avseende på dess effekt på tumören, biverkningsprofil och 
hälsorelaterad livskvalitet. Vinflunine undersöktes som singel-behandling och i nya 
behandlingskombinationer vid metastaserad sjukdom. Vidare utvärderades två olika 
cellgiftskombinationer vid muskelinvasiv sjukdom. 
I Studie I analyserades användandet av den nyligen introducerade cytostatikan vinflunine i 
klinisk rutinsjukvård genom att studera tumöreffekt, behandlingsmönster och biverkningar. 
Vinflunine var effektivt i klinisk rutin och förlängde överlevnaden i samma storleksordning 
som i den originalstudie som låg till grund för godkännandet av vinflunine. Patienter med 
dåligt allmäntillstånd hade kortare överlevnad och drabbades av fler biverkningar än patienter 
med bra allmäntillstånd.  
I Studie II studerades vinflunine i en ny kombination med det målstyrda läkemedlet 
sorafenib i en nordisk läkemedelsstudie för patienter med metastaserad urinblåsecancer som 
sviktat på tidigare platinumbaserad cytostatikabehandling. Då denna nya behandlings-
kombination aldrig getts till patienter tidigare var studiens huvudsakliga mål att analysera 
biverkningsprofilen och bestämma vilka doser av de två ingående läkemedlen som var 
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lämpliga att ge. Vinflunine tillsammans med sorafenib kunde ges på ett säkert sätt och 
biverkningarna var i linje med vad som tidigare är beskrivet för vart och ett av läkemedlen. 
Denna nya behandlingskombination är lovande och bör undersökas i ytterligare studier med 
fokus på dess tumörkrympande effekt och överlevnad hos patienter med metastaserad 
urinblåsecancer. 
I Studie III undersöktes vinflunine i en ny kombination med cytostatikan gemcitabine hos 
patienter med metastaserad urinblåsecancer i en stor nordisk läkemedelsstudie. Patienterna 
lottades till antingen behandling med den nya experimentella behandlingen eller till dagens 
standardbehandling, som utgörs av cytostatikakombinationen gemcitabine och karboplatin. 
Vinflunine tillsammans med gemcitabine ledde inte längre överlevnad jämfört med dagens 
standardbehandling, men däremot minskade storleken av tumörerna i markant högre grad hos 
patienter som erhöll den experimentella behandlingen. Biverkningsprofilen var acceptabel 
för den nya kombinationen, även om en högre andel av patienterna drabbades av låga vita 
blodkroppar och till följd av detta infektioner. Trots skillnaderna i biverkningsprofilen 
uppmättes den hälsorelaterad livskvalitet som likvärdig mellan de två behandlingsgrupperna. 
Med tanke på att kombination vinflunine och gemcitabine minskade tumörstorleken mycket 
effektivt vore det intressant att undersöka denna nya kombination i ytterligare studier vid 
muskelinvasiv och metastaserad urinblåsecancer. 
I Studie IV jämfördes behandling mellan två olika scheman av cytostatikakombinationen 
gemcitabine och cisplatin hos patienter med muskelinvasiv sjukdom innan bortoperation av 
urinblåsan. Patienter som erhöll behandling med ett mer dosintensivt 3-veckors schema 
erhöll en bättre krympande effekt på tumören i urinblåsan, dock även med fler biverkningar, 
än patienter som erhöll ett 4-veckors schema. Trots skillnad i effekt på tumören i urinblåsan 
kunde ingen skillnad ses i andelen patienter som drabbades av återfall eller dog av sjukdomen 
mellan de två olika behandlingsschemana. 
Sammanfattningsvis bidrar denna doktorsavhandling med ny kunskap om effekten och 
biverkningsprofilen av vinflunine som singelbehandling och i nya lovande behandlings-
kombinationer hos patienter med metastaserad urinblåsecancer, samt ny kunskap om den 
tumörkrympande effekten av cytostatikakombinationen gemcitabine och cisplatin hos 
patienter med muskelinvasiv sjukdom. De senaste åren har utvecklingen av behandlings-
alternativ vid metastaserad urinblåsecancer gått mycket snabbt. Förutom immunterapi som 
redan etablerat sig som en av standardbehandlingarna i klinisk rutin, är flertalet andra 
läkemedel, främst så kallade målriktade läkemedel, på väg att godkännas inom kort. 
Metastaserad urinblåsecancer är en sjukdom med ofta mycket svåra cancerrelaterade symtom 
och trots nya behandlingsalternativ är överlevnaden begränsad. Det är därför av största vikt 
att utveckla nya behandlingar som både förlänger livet och förbättrar patienternas 
hälsorelaterade livskvalitet. 
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 APPENDIX A 
 Participating centres associated with the NUCOG collaboration 
 
 Paper I Paper II Paper III Paper IV 
Sweden     
Karolinska Universitetssjukhuset, Stockholm x x x x 
Norrlands Universitetssjukhus, Umeå   x  
Sahlgrenska Universitetssjukhus, Göteborg   x  
Skånes Universitetssjukhus, Malmö/Lund   x  
Västmanlands Sjukhus, Västerås   x  
Denmark     
Aalborg Universitetshospital, Aalborg   x x 
Aarhus Universitetshospital, Aarhus  x x x 
Herlev Gentofte Hospital, Herlev   x x 
Odense Universitetshospital, Odense x  x x 
Rigshospitalet, Copenhagen x x x x 
Finland     














Patients treated with vinflunine in the Nordic countries: A retrospective study 
__________________________________________________________________________ 
Date of registration:  __________________________        Name of registrant:   _________________________ 
Participating centre: __________________________ 
__________________________________________________________________________ 
1. GENERAL INFORMATION (at time of diagnosis, at least muscle-invasive disease) 
Gender: Male    Female  
Date of diagnosis:_____________ 
Age at diagnosis: _____________  
Primary tumour location: Bladder   Urethra    Ureter   Renal pelvis   Urachus   Other  ________ 
Histology:  Transitional cell carcinoma  Adenocarcinoma  Urachal adenocarcinoma                            
Small cell carcinoma  Squamous cell carcinoma  Sarcomatoid carcinoma                     
TCC with neuroendocrine features  TCC with squamous differentiation                              
TCC with glandular differentiation  TCC with sarcomatoid differentiation                        
TCC with micropapillary features  Pure micropapillary  Other  
Clinical Stage at diagnosis:  T2a–T4b:__________  N0–N3:__________   M0–M1:__________ 
__________________________________________________________________________ 
2. PRIMARY TREATMENT 
Surgical removal of primary tumour (cystectomy):  Yes   No        
Radiation therapy to primary tumour: Yes   No                    
Concurrent Chemotherapy with radiation therapy: Yes   No   Chemotherapy regimen:________________ 
PERIOPERATIVE SYSTEMIC THERAPY 
Neoadjuvant therapy:  Yes   No       Chemotherapy regimen:__________________________ 
Adjuvant therapy?       Yes   No       Chemotherapy regimen:__________________________ 
__________________________________________________________________________ 
3. METASTATIC DISEASE/RECURRENCE 
Date of diagnosis of first metastatic or locally recurrent disease:______________ 
Metastatic sites:  Local recurrence bladder        
  Lymph nodes     Liver     Lung     Bone     Brain     Other ___________ 
_________________________________________________________________________________________ 
4. SYSTEMIC THERAPY (prior to vinflunine therapy) 
FIRST-LINE SYSTEMIC THERAPY 
Was first-line chemotherapy administered?  Yes   No             
First-line cisplatin-based regimen:_________________________________        Number of Cycles:________ 
Reason for discontinuation: Progressive disease    Toxicity    Other  ____________________________ 
First-line carboplatin-based regimen:_______________________________       Number of Cycles:________     
Reason for carboplatin-based regimen:  Impaired renal function  Performance status > 1   
             Comorbidity   Other  ______________________                         
Reason for discontinuation:  Progressive disease    Toxicity    Other  ___________________________ 
First-line single gemcitabine regimen:____________________________       Number of Cycles:________     
Reason for single gemcitabine regimen: Impaired renal function  Performance status > 1   
              Comorbidity   Other  ______________________                         
Reason for discontinuation:  Progressive disease    Toxicity    Other  ________________________ 
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Other first-line chemotherapy regimen:____________________________    Number of cycles:________     
Reason for other chemotherapy regimen:   Impaired renal function  Performance status > 1   
                  Comorbidity   Other  ______________________                         
Reason for discontinuation:  Progressive disease    Toxicity    Other  _________________________ 
SECOND-LINE SYSTEMIC THERAPY 
Was second-line chemotherapy administered? Yes No            
Second-line chemotherapy regimen:________________________________   Number of cycles:_______ 
Reason for discontinuation: Progressive disease    Toxicity    Other  _________________________ 
THIRD-LINE SYSTEMIC THERAPY 
Was third-line chemotherapy administered? Yes No        
Third-line chemotherapy regimen:________________________________    Number of cycles:________ 
Reason for discontinuation:  Progressive disease    Toxicity    Other  ________________________ 
PLATINUM RESISTANCE 
Relapse or progression within 6 months after carboplatin or cisplatin-based chemotherapy: Yes No    
_________________________________________________________________________________________ 
5. BASE-LINE PARAMETERS VINFLUNINE TREATMENT             
Age:______          ECOG PS:____________          Prior pelvic/abdominal irradiation: Yes   No  
GFR (iohexol or Cr-EDTA clearance, ml/min):________ 
Alkaline phosphatase :  Normal      Elevated      Haemoglobin: < 100     ≥ 100 
Metastatic sites:  Local recurrence bladder        
  Lymph nodes     Liver     Lung     Bone     Brain     Other ____________ 
Relevant comorbidity: ________________________________________________________________ 
__________________________________________________________________________ 
6. VINFLUNINE TREATMENT                                                            
Vinflunine given as: first line       second line      third line     fourth line  
Initial dose of vinflunine:  320 mg/m2     280 mg/m2     250 mg/m2    
Number of cycles:_______  
Date of starting vinflunine:   ____________         Date of discontinuing vinflunine: ____________ 
                                             
Dose reduction: Yes   No       
Dose delay (≥ 1 week): Yes   No         
Reason for dose reduction and/or dose delay:  Related to the vinflunine treatment  
   Related to the bladder cancer disease  
   Other  ________________________ 
Re-challenge of vinflunine: Yes   No      
Length of pause (weeks since previous vinflunine treatment period was discontinued): _________ 
Dose of vinflunine when re-challenged:  320 mg/m2     280 mg/m2     250 mg/m2    
Number of cycles when re-challenged:_______ 
Date of starting vinflunine:   ____________              Date of discontinuing vinflunine: ___________
                                                 
Dose reduction when re-challenged: Yes   No       
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Dose delay when re-challenged (≥ 1 week): Yes   No      
Reason for dose reduction and/or dose delay when re-challenged: Related to the vinflunine treatment 
                             Related to the bladder cancer disease 
                             Other  ________________________ 
__________________________________________________________________________________________ 
7. TERMINATION OF VINFLUNINE TREATMENT 
Total number of cycles:_______         
Reason for discontinuing:  Progressive disease    Toxicity    Other  ______________________________ 
_________________________________________________________________________________________   
8. OTHER ONCOLOGICAL TREATMENTS (during vinflunine treatment) 
Palliative radiotherapy: Yes No       Bisphosphonates: Yes No     Other: _____________________ 
__________________________________________________________________________ 
9. PAIN 
Pain at baseline (when initiating vinflunine): Yes    No    
Pain reduction during/after vinflunine: Yes    No    
__________________________________________________________________________ 
10. TREATMENT-RELATED TOXICITY (grade 3/4 AEs related to vinflunine treatment) 
Anaemia: Yes No    Neutropenia: Yes No   Febrile neutropenia: Yes No                 
Thrombocytopenia: Yes No     
Fatigue: Yes No    Nausea: Yes No   Vomiting: Yes No   Stomatitis/Mucositis: Yes No    
Abdominal pain: Yes No    Constipation: Yes No     
Myalgia: Yes No   Neuropathy sensory: Yes No     
Alopecia: Yes No    Infusion/Injection site reaction: Yes No    
__________________________________________________________________________ 
11. EFFICACY RESULTS (of vinflunine treatment) 
Evaluation no. 1  Total number of cycles:________             Evaluation no. 2   Total number of cycles:________                     
Complete response: Yes No                         Complete response: Yes No  
Partial response: Yes No                       Partial response: Yes No    
Stable disease: Yes No                       Stable disease: Yes No  
Progress: Yes No                       Progress: Yes No    
Evaluation no. 3  Total number of cycles:________              Evaluation no. 4  Total number of cycles:________                
Complete response: Yes No                         Complete response: Yes No 
Partial response: Yes No                       Partial response: Yes No   
Stable disease: Yes No                       Stable disease: Yes No  
Progress: Yes No                       Progress: Yes No    
Evaluation no. 5  Total number of cycles:________               Evaluation no. 6  Total number of cycles:________                 
Complete response: Yes No                          Complete response: Yes No 
Partial response: Yes No                        Partial response: Yes No   
Stable disease: Yes No                        Stable disease: Yes No  
Progress: Yes No                        Progress: Yes No    
Duration of response = Complete response and/or partial response (weeks):__________ 
Progression-free survival (PFS) = Complete response and/or partial response and/or stable disease (weeks):____ 
__________________________________________________________________________ 
12. SURVIVAL STATUS 




VARIABLE TEMPLATE NUCOG V  
3- vs 4-week GC as neoadjuvant treatment in muscle invasive bladder cancer 
All dates are registered as yyyy-mm-dd! 
BASELINE PARAMETERS 
1. Patient study ID  
2. Age at start of neoadjuvant chemotherapy 
3. Sex 
4. ECOG at start of neoadjuvant (0 or 1) 
5. cTNM at start of neoadjuvant 
6. GFR at start (iohexole clearance [uncorrected] or chrome-EDTA if available, otherwise 
calculated GFR) 
TREATMENT PATTERNS 
7. Date of first cycle of neoadjuvant chemotherapy 
8. Date of last given neoadjuvant chemotherapy (date of last infusion of cisplatin or 
gemcitabine) 
9. Total number of cycles (despite dose reductions, dose delays, omitted doses, etc.) 
10. Number of cycles with d 8 given 
11. Reason if d 8 not given, more than one reason possible (more than one cycle with 
omitted d 8 or more than one reason for omitting d 8 at the same cycle):  
anaemia = 1; neutropenia = 2; thrombocytopenia =3; neutropenic fever = 4; 
infection = 5; decreased kidney function = 6; other reason = 7. 
12. Number of cycles with reduction of cisplatin dose 
13. Reason for cisplatin dose reduction, more than one reason possible (more than one 
cycle with dose reduction or more than one reason for dose reduction during the same 
cycle): 
anaemia = 1; neutropenia = 2; thrombocytopenia =3; neutropenic fever = 4; 
infection = 5; decreased kidney function = 6; other reason = 7. 
14. Number of cycles with reduction of gemcitabine dose 
15. Reason for gemcitabine dose reduction, more than one reason possible (more than one 
cycle with dose reduction or more than one reason for dose reduction during the same 
cycle): 
anaemia = 1; neutropenia = 2; thrombocytopenia =3; neutropenic fever = 4; 
infection = 5; decreased kidney function = 6; other reason = 7. 
16. Number of cycles with dose delay 
17. Reason for dose delay (5 days or more), more than one reason possible (more than one 
cycle with dose delay or more than one reason for dose delay during the same cycle): 
anaemia = 1; neutropenia = 2; thrombocytopenia =3; neutropenic fever = 4; 
infection = 5; decreased kidney function = 6; other reason = 7. 
18. Number of cycles with C-GSF 
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19. Terminated treatment prematurely (yes/no) 
If yes, type the reason for premature termination, more than one reason possible: 
anaemia = 1; neutropenia = 2; thrombocytopenia =3; neutropenic fever = 4; 
infection = 5; decreased kidney function = 6; thromboembolic event = 7; hearing 
loss = 8; peripheral neuropathy = 9; heart failure = 10; progressive disease = 11; 
other reason = 12. 
TOXICITY Register toxicity if it appears at least once in the same patient. Do NOT register 
single blood values! 
20. Anaemia grade 3/4 (haemoglobin < 4.9 mmol/L or < 80 g/L) (yes/no) 
21. Neutropenia grade 3/4 (neutrophils < 1.0 x 10e9 /L) (yes/no) 
22. Febrile neutropenia (neutrophils < 1.0 x 10e9 /L and a single temperature of 38.5 
degrees or sustained temperature of ≥ 38 degrees for more than 1 hour) (yes/no) 
23. Thrombocytopenia grade 3/4 (thrombocytes < 50 x 10e9 /L) (yes/no) 
24. Non-haematological AE (NH-AE) grade 3/4 (yes/no) 
          If yes, type of NH-AE:  
infection = 1; thromboembolic event = 2; decreased  kidney function = 3; hearing 
loss = 4; peripheral neuropathy = 5; heart failure = 6; other reason = 7.  
25. Death related to neoadjuvant treatment (yes/no)  
OUTCOME MEASUREMENT 
26. Date of cystectomy 
27. pT (pT0, pT1, pT2, pT3, pT4, pTIS, pTa) 
28. pN (pN0, pN1, pN2, pN3) 
29. Relapse (yes/no) 
30. Date of relapse (date of radiology, biopsy, or obvious clinical progression) 
31. Death (yes/no) 
32. Death due to bladder cancer (yes/no) 
33. Date of death  











           EORTC QLQ-C30 (version 3) 
We are interested in some things about you and your health. Please answer all of the questions yourself 
by circling the number that best applies to you. There are no "right" or "wrong" answers. The 
information that you provide will remain strictly confidential. 
 
Please fill in your initials:  
Your birthdate (Day, Month, Year):  




1. Do you have any trouble doing strenuous activities, 






like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside  
of the house? 
1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4 
5. Do you need help with eating, 



















 All Little a Bit Much 
6. Were you limited in doing either your work or other 
daily activities? 
1 2 3 4 
7. Were you limited in pursuing 










8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
16. Have you been constipated? 1 2 3 4 





For the  following  questions  please  circle  the  number  between   1  
and  7  that   best applies to you 
29. How would you rate your overall health during the past week? 
 
1 2 3 4 5 6 7 
 
Very poor Excellent 
 
 
30. How would you rate your overall quality of life during the past week? 
 
1 2 3 4 5 6 7 
 
Very poor Excellent 
 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
 
During the past week: 
 
17. Have you had diarrhea? 















18. Were you tired? 1 2 3 4 
19. Did pain interfere with your daily activities? 1 2 3 4 
 20. Have you had difficulty in 
concentrating on things, like reading a 









21. Did you feel tense? 1 2 3 4 
22. Did you worry? 1 2 3 4 
23. Did you feel irritable? 1 2 3 4 
24. Did you feel depressed? 1 2 3 4 
25. Have you had difficulty remembering things? 1 2 3 4 
26. Has your physical condition or 










27. Has your physical condition or 










28. Has your physical condition or 
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blåscancer – en retrospektiv kvalitetssäkringsanalys 
02-05-2013  
Denmark  Letter from professor H. Pappot concerning the 











Tidig klinisk prövning av tolerabilitet samt analys av 
biomarkörer vid behandling av avancerad cancer 
utgången från urinvägarna med standardcytostatika 
vinflunine (Javlor®) med tillägg av 
cancerläkemedlet sorafenib (Nexavar®) 
12-10-2011 
 
Läkemedelsverket 151:2012/12127 Klinisk prövning av Javlor 05-03-2012 
Center for Sundhed, 
De Videnskabsetiske 
Komiteer i Region 
Hovedstaden, 
Copenhagen 
Protokol nr.:  
H-1-2012-079 
”Tidlig klinisk afprøvning af tolerabilitet ved 
behandling af metastatisk kræft udgående fra 
urinvejene med en ny kombination: 








“An Exploratory Phase I Study with Sorafenib in 
Addition to Vinflunine in Progressive Locally 
Advanced or Metastatic Transitional Cell Carcinoma 









A multicentre, randomised phase II trial of 
vinflunine/gemcitabine versus carboplatin 
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